

The Liver Week 2015 September 10-12

September 10 -12, 2015 BEXCO, Busan, Korea

The 21st Annual Meeting of the Korean Association for the Study of the Liver The Korean Association of HBP Surgery Symposium The 18th General Symposium of the Korean Liver Cancer Study Group The Korean Liver Transplantation Society Symposium









Welcome Message



September 10 (Thu) -12 (Sat), 2015 BEXCO, Busan, Korea

Dear Colleagues,

On behalf of the Organizing Committee of The Liver Week 2015, we are pleased to welcome you to The Liver Week 2015 to be held on September 10-12, 2015 at BEXCO, Busan, Korea.

Continuing from The Liver Week 2014, The Korean Association for the Study of the Liver (KASL) will be hosting The Liver Week 2015 alongside with three co-hosting societies, The Korean Association of HBP Surgery (KHBPS), The Korean Liver Cancer Study Group (KLCSG), and The Korean Liver Transplantation Society (KLTS).

The Liver Week 2015 will also celebrate the 20th Anniversary of the founding of the KASL jointly under the theme of "Curing Liver Disease: Past to the Future". With this intergrated effort, we intend to provide a platform to reflect and debate our latest studies and knowledge for the better future.

We hope that you would be able to benefit greatly from our program and make the most of your time in Busan, Korea's largest port city with abundance of coastal tourist attractions, historical and cultural sites, and trendy shopping areas.

Welcome to the Liver Week 2015!



Kwang-Hyub Han

President, The Liver Week 2015 President, The Korean Associati for the Study of the Liver



Ja-June Jang

Ja-June Jang Chairman, The Liver Week 2015 Chairman, The Korean Association for the Study of the Liver



Hee Jung Wang




Syly 4.2 Kyung-Suk Suh



Soon Ho Um




Soon Kim











Organizing Committee

Congress Chairman	Ja-June Jang			
President	Kwang-Hyub Han			
Vice President	Kyung-Suk Suh	Hee Jung Wang	Soon Ho Um	Soon Il Kim
Secretary General	Seung Kew Yoon Hyung Joon Yim	Bong Wan Kim Dong Jin Joo	Nam-Joon Yi	Yoon Jun Kim
Scientific Committee	Soon Koo Baik (Chair) Shin Hwang	Kwang-Woong Lee	Jin-Young Jang	Do Young Kim
Organizing Committee Members	Sang Hoon Ahn Donglak Choi Hojong Chun Dong Joon Kim Young Seok Kim Young-Suk Lim Hee Chul Yu	Si Hyun Bae In Seok Choi Jin Seok Heo Jin-Wook Kim Kuk Hwan Kwon Deok-Bog Moon	Yong Kyun Cho Jong Young Choi Byoung Kuk Jang Kyung Sik Kim Hyeon Kook Lee Sang-Jae Park	Won Hyeok Choe Chong Woo Chu Jae-Won Joh Sang Geol Kim Woo-Jung Lee Myunghee Yoon

Program at a Glance



DAY 1 Thursday, September 10, 2015

K : Session in Korean E : Session in English

	ROOM 1	ROOM 2	ROOM 3	ROOM 4	ROOM 5	ROOM 6	ROOM 7	ROOM 8
09:00								
10:00—	KASL-EASL Joint Meeting ^[E] Recent Perspectives in Noninvasive Diagnosis of Cirrhosis and HCC Sub-classification (09:00-10:20)	Viral Hepatitis Forum I (E) Hepatitis C Virus: From Discovery to Eradication (09:00–10:20)						
_			Coffee Break (10:20-10	0:40)				
11:00 —	Symposium 1 ^[E] Consensus Meeting on the Noninvasive Diagnosis of Cirrhosis (10:40-12:00)	Viral Hepatitis Forum II (E) Hepatitis B Virus: From Discovery to Eradication (10:40-12:00)	Short Course ^{KI} Comprehension of Korean Healthcare R&D Project (10:40-12:00)					
12:00—								
13:00—	Luncheon Symposium 1 [by Gilead] (12:00-13:10)	Luncheon Symposium 2 [by Celltrion-Hanmi] [12:00-13:10]						
	Opening Ceremony							
14:00—	Special Lecture 1 ^[E] (13:30-14:00)	Asia-pacific Joint Symposium [5] I. HBV: Immuno- and Bio-therapeutic Approach to Cure Chronic HBV Infection						
15:00—	Plenary Session 1 ^(E) (14:00-15:30)	(13:30-14:30) II. Management of Chronic Hepatitis C: Clinical Issues and Future Perspective (14:30-15:30)						
16:00—		Coffee B	Break & Poster Oral P (15:30-16:30)	resentation I				
17:00—	Symposium 2 ^E Liver-Gut Axis (16:30-17:50)	III. Management of Chronic Hepatitis B: Clinical Issues and Future Perspective (16:30-17:50)	Clinical Hepatology Update ^{KI} ASH and NASH (16:30-17:50)	Free Paper 1 HCV (16:30-18:00)	Free Paper 2 Cell Biology, Molecular Biology [16:30-18:00]	Free Paper 3 Acute Liver Disease, Liver Failure, LT, Others [16:30-18:00]	Free Paper 4 Liver Cancer, Basic (16:30-18:00)	Free Paper 5 Liver Cancer, Clinical (I) (16:30-18:00)
18:00—	Dinner Symposium [by Bayer] (18:00-19:40)							



DAY 1 Thursday, September 10, 2015

ROOM 1

00 00 10 00		
09:00-10:20	KASL-EASL Joint Meeting E Recent Perspectives in Noninvasive Diagnosis of Cirrho Laurent Castera (Univ. of Par	osis and HCC Sub-classification ris-VII, France), Kwang-Hyub Han (Yonsei Univ.
09:00 - 09:20	Functional US-based Diagnosis of PH and Cirrhotic Complication	Soon Koo Baik, Yonsei Univ. Wonju
09:20 - 09:40	EASL-ALEH Clinical Practice Guidelines on Noninvasive Evaluation of Liver Disease	Laurent Castera, Univ. of Paris-VII, France
09:40-10:00	Prognostic Markers in HCC and Their Application to Clinical Practice	Markus Peck, Medical Univ. of Vienna, Austric
10:00-10:20	Sub-classification of Intermediate and Advanced HCC: Rationale and Strategy	Do Young Kim, Yonsei Univ
10:40-12:00	Symposium 1 ^[E] Consensus Meeting on the Noninvasive Diagnosis of Cirrhosis Laurent Castera (Univ. of Pari	s-VII, France), Kwang-Hyub Han (Yonsei Univ.,
10:40-11:05	Noninvasive Tools for the Diagnosis of Cirrhosis: Is TE Not Enough by Itself?	Laurent Castera, Univ. of Paris-VII, France
11:05-11:30	Optimal Cutoff Value of TE for the Diagnosis of Cirrhosis	Do Young Kim, Yonsei Univ
11:30-11:55	Noninvasive Evaluation of Liver Fibrosis in China	Jun Cheng, Capital Medical Univ., China
11:55-12:00	Discussion	
12:00-13:10	Luncheon Symposium 1 [by Gilead]	
13:10-13:30	The Liver Week 2015 Opening Ceremony	
13:30-14:00	Special Lecure 1 [E]	Byung Chul Yoo (Konkuk Univ.)
	Acute on Chronic Liver Failure Richard Moreau, National Institute for	or Health and Medical Research (INSERM), France
14:00-15:30	Plenary Session 1 ^[E] PART 1 : Chun-Jen Liu (National Taiwan Univ., Taiwan), Haak Cheoul Kim (Wonkwang Univ.), Kwan S	St. A
	PART 2 : Robert Schwabe (Columbia Univ., USA), Markus Peck (Medical Univ. of Vienna, Austria), Byt	*
16:30-17:50		
16:30-17:50 16:30-16:50		ung Ik Kim (Sungkyunkwan Univ.) ada), Dae-Ghon Kim (Chonbuk National Univ.
	Symposium 2 ^[E] Liver-Gut Axis Samuel Lee (Univ. of Calgary, Canal	ung Ik Kim (Sungkyunkwan Univ.) ada), Dae-Ghon Kim (Chonbuk National Univ. Robert Schwabe, Columbia Univ., USA
16:30-16:50	Symposium 2 ^[E] Liver-Gut Axis Samuel Lee (Univ. of Calgary, Canal Microbiome and the Liver-Clinical Implications	ung Ik Kim (Sungkyunkwan Univ.) ada), Dae-Ghon Kim (Chonbuk National Univ. Robert Schwabe, Columbia Univ., US/ GwangPyo Ko, Seoul National Univ
16:30-16:50 16:50-17:10	Symposium 2 Liver-Gut Axis Samuel Lee (Univ. of Calgary, Canal Microbiome and the Liver-Clinical Implications Cutting-edge Methods of Human Microbiota Research Using Korean Twins	ung Ik Kim (Sungkyunkwan Univ.)

09:00-10:20	Viral Hepatitis Forum I 🗉 HCV: From Discovery to Eradication	Lai Wei (Peking Univ., China), Soon Bong Hwang (Hallym Univ.)
09:00-09:20	HCV: Virus Life Cycle and Targets of DAA	Seungtaek Kim, Yonsei Univ
09:20-09:40	History of Drugs: From Interferon to DAA	Lai Wei, Peking Univ., China
09:40-10:00	Treatment Options: West vs. East	W. Ray Kim, Stanford Univ., USA
10:00-10:20	Hepatitis C Virus Coopts Host Ankyrin Repeat Domain 1 for Its Own P	ropagation Soon Bong Hwang , Hallym Univ.
10:40-12:00	Viral Hepatitis Forum II E HBV: From Discovery to Eradication Antonio Bertoletti (Duke-Nu	s Graduate Medical School, Singapore), Kwan Soo Byun (Korea Univ.)
10:40-11:00	The Virus and Pathogenesis	Yasuhito Tanaka, Nagoya City Univ., Japan
11:00-11:20	Treatment: Two Decades of Progress	Jia-Horng Kao, National Taiwan Univ., Taiwan
11:20-11:40	Revisit Quantitative HBsAg and cccDNA	Man-Fung Yuen, The Univ. of Hong Kong, Hong Kong
11:40-12:00	New Trials Toward a Cure	Sang Hoon Ahn, Yonsei Univ.



DAY 1 Thursday, September 10, 2015

ROOM 2

12:00-13:10	Luncheon Symposium 2 [by Celltrion-Hanmi]	
13:30-14:30	Asia-pacific Joint Symposium ^[E] I. HBV: Immuno-and Bio-therapeutic Approach to Cure Chronic HBV Infection Pei-Jer Chen (National Taiwan Univ., Taiwa	an), Seung Kew Yoon (The Catholic Univ. of Korea)
13:30-13:50	Immunopathogenesis of HBV Infection and Principle of Immunotherapy for HBV Infection Antonio Bertolett	i, Duke-Nus Graduate Medical School, Singapore
13:50-14:10	Clinical Experience of HBV DNA Vaccine in Korean Patients with Chronic HBV Infection	Seung Kew Yoon, The Catholic Univ. of Korea
14:10-14:30	Optimized Immunotherapy to Cure Chronic HBV Infection by Using a Convenient Immuno-competent Mouse Model	Pei-Jer Chen, National Taiwan Univ., Taiwan
14:30-15:30	II. Management of Chronic Hepatitis C: Clinical Issues and Future Perspective W. Ray Kim (Stanford Un	iv., USA), Seung Woon Paik (Sungkyunkwan Univ.)
14:30-14:50	Hepatitis C: National-wide Screening of HCV	Lai Wei, Peking Univ., China
14:50-15:10	Hepatitis C: Interferon-based Regimens, Still Useful or Useless?	Young Seok Kim, Soonchunhyang Univ.
15:10-15:30	Future Use of DAAs in Asia-Pacific Region	Ming-Lung Yu, Kaohsiung Medical Univ., Taiwan
16:30-17:50	III. Management of Chronic Hepatitis B: Clinical Issues and Future Perspective Jia-Horng Kao (National)	Taiwan Univ., Taiwan), Sung Won Cho (Ajou Univ.)
16:30-16:50	Management of Chronic Hepatitis B: Nation-wide Cohort Studies	Chun-Jen Liu, National Taiwan Univ., Taiwan
16:50-17:10	Management of HBV Antiviral Resistance	Young-Suk Lim, Univ. of Ulsan
17:10-17:30	HBV Treatment Initiation and Cessation Criteria Qin Ning, I	Huazhong Univ. of Science and Technology, China
17:30-17:50	Beyond the Antiviral Therapy to Reduce the Risk of Liver Cancers in Chronic Hepatitis B	Shiou-Hwei Yeh, National Taiwan Univ., Taiwan

10:40-12:00	Short Course (K) Comprehension of Korean Healthcare R	&D Project Chang-Min Kim (National Cancer Center), Soon Koo Baik (Yonsei Univ. Wonju)
10:40-11:00	The Necessity of Research Support to Overcome the Live 국내 간질환 극복을 위한 연구지원의 필요성	r Disease in Korea Young-Suk Lim, Univ. of Ulsan
11:00-11:20	Understanding and Activation Strategies of Disease-orier 질병중심 중개연구의 이해 및 활성화 전략	nted Translational Research Seong Yun Kim, Korea Health Industry Development Institute
11:20-11:40	Big Data Management 빅데이터 관리	Log-Young Kim, The Health Insurance Review and Assessment Service of Korea
11:40-12:00	Discussion	
11:40-12:00	Discussion Clinical Hepatology Update (K) ASH and NASH	Heon Ju Lee (Yeungnam Univ.), Joo Hyun Sohn (Hanyang Univ.)
		Heon Ju Lee (Yeungnam Univ.), Joo Hyun Sohn (Hanyang Univ.) Won Kim, Seoul National Univ.
16:30-17:50	Clinical Hepatology Update ^(K) ASH and NASH	
16:30-17:50 16:30-16:50	Clinical Hepatology Update (K) ASH and NASH Mechanism-based New Target for Therapy in ASH	Won Kim, Seoul National Univ.



Program at a Glance

DAY 2 Friday, September 11, 2015

K : Session in Korean E : Session in English

	ROOM 1	ROOM 2	ROOM 3	ROOM 4	ROOM 5	ROOM 6	ROOM 7	ROOM 8
07:30	* Poster Oral Presentation II (08	:00-09:00)		EMW 1 ^(E)	EMW 2 ^(E)	EMW 3 (E)	EMW 4 (E)	
08:00—				HBV	HCV	Portal Hypertension	Acute on Chronic Liver Failure	
09:00					* EM	W: Early Mornir	ng Workshop	
10:00—	Symposium 3 ^(E) Debates in the Treatment of Portal Hypertension (09:00-10:20)	KASL & KSSCR Joint Symposium (K) Liver Regeneration: Where We Are (09:00-10:20)	KLTS Symposium ^(E) HCC Recurrence after Liver Transplantation (09:00-10:20)	Free Paper 6 Liver Cancer, Clinical (II) (09:00-10:30)	Free Paper 7 Surgery (I) (09:00-10:30)	HBV (I)	Free Paper 9 HBV (II) (09:00-10:30)	Free Paper 10 Cirhosis, Liver Fibrosis (I) (09:00-10:30)
-			Coffee Break (10:20-10:40)					
11:00 —	Plenary Session 2 [5] [10:40-12:10]	KLTS Coordinator Program ^[K] The Role of Coordinator in Liver Transplant Field	KHBPS & KLTS Joint Symposium [E] Care for Long-term Survivor after Liver Transplantation	Free Paper 11 Liver Cancer, Clinical (III) (10:40-12:10)	Free Paper 12 Surgery (II) (10:40-12:10)			
12:00—		(10:40-12:10)	(10:40-12:10)	(10.40-12.10)				
13:00—	Luncheon Symposium 3 [by BMS] (12:10-13:30)	Luncheon Symposium 4 [by MSD] (12:10-13:30)	Luncheon Symposium 5 [by Novartis] (12:10-13:30)					
14:00—	Special Lecture 2 ^[E] (13:30-14:30)	Plenary Session 3 ^(E) Multidisciplinary Approach to Liver Cancer	KHBPS & JSHBPS Joint Symposium 1 [E] (13:30-14:15) KHBPS & JSHBPS	Plenary Session 3 ^(E) Multidisciplinary Approach to Liver Transplantation				
15:00—	State-of-the-Art Lecture (E) (14:30-15:00)	(13:30-15:00)	Joint Symposium 2 ^[E] (14:15-15:00)	(13:30-15:00)				
10.00			Coffee Break (15:00-15:	30)				
16:00—	KASL 20th Anniversary Commemorative Symposium IKI		KHBPS & JSHBPS Joint Symposium 3 ^(E) (15:30-16:15)					
_	Past, Present and Future in KASL (15:30-17:00)							
17:00			Cocktail Reception					





Early Morning Workshop (E) *Breakfast will be served.

07:30-08:30	Workshop 1 [HBV]	Seong Gyu Hwang (CHA Univ.)
07:30-08:00	When to Stop NUCs: Is It Possible?	Yasuhito Tanaka, Nagoya City Univ., Japan
08:00-08:30	How to Monitor for Stopping NUCs	Jun Yong Park, Yonsei Univ.
07:30-08:30	Workshop 2 [HCV]	Sook-Hyang Jeong (Seoul National Univ.)
	HCV Immunology Related with Therapeutic Agents: Is It Impossible to Get Real Immunity Against HCV?	Ming-Lung Yu, Kaohsiung Medical Univ., Taiwan
07:30-08:30	Workshop 3 [Portal Hypertension]	Joo Hyun Sohn (Hanyang Univ.)
	Hyperdynamic Circulation	Samuel Lee, Univ. of Calgary, Canada
07:30-08:30	Workshop 4 [Acute-on-Chronic Liver Failure]	Dong Joon Kim (Hallym Univ.)
	Questions, Controversies, and Future Researches	Richard Moreau, National Institute for Health and Medical Research (INSERM), France

ROOM		
09:00-10:20	Symposium 3 ^(E) Debates in the Treatment of Portal Hypertension Richard Moreau (National Institute for Health and	Medical Research (INSERM), France), Soon Ho Um (Korea Univ.)
09:00-09:20	Antibiotic Prophylaxis: Which Drug, For Whom, For How Long?	Won Hyeok Choe, Konkuk Univ.
09:20-09:40	Coagulopathy: Is It a Complication or a Treatment Target?	Samuel Lee, Univ. of Calgary, Canada
09:40-10:00	Minimal Hepatic Encephalopathy Should Be Treated or Not?	B. C. Sharma, G.B. Pant Hospital, India
10:00-10:20	Radiological Intervention: When Should It Be Considered in Patients with Complications of Portal H	ypertension? Sung Ki Cho, Sungkyunkwan Univ.
10:40-12:10	Plenary Session 2 ^[E] PART 1 : Choong Kee Park (Hallym Univ.), Young Oh Kweon (Kyungpook National Univ.) PART 2 : Heon Young Lee (Chungnam National Univ.), Kwang Cheol Koh (Sungkyunkw	
12:10-13:30	Luncheon Symposium 3 (by BMS)	
13:30-14:30	Special Lecture 2 ^[E] Emerging Trends in Treatments of Chronic Liver Dis	sease Young-Hwa Chung (Univ. of Ulsan)
13:30-13:50	New Paradigms for Hepatitis C	W. Ray Kim, Stanford Univ., USA
13:50-14:10	The Evolution of HCC Treatment	Masatoshi Kudo, Kinki Univ., Japan
14:10-14:30	Fifty Years of Japanese Hepatology: Past, Present and Future	Kazuhiko Koike, The Univ. of Tokyo, Japan
14:30-15:00	State-of-the-art Lecture (E)	Kwang-Hyub Han (Yonsei Univ.)
14:30-15:00	Noninvasive Tools for the Diagnosis and Management of Cirrhosis	Laurent Castera, Univ. of Paris-VII, France
15:30-17:00	TV 102 20 th 7 th miter out y commenter duty cymposium	multaneous interpretation service in English will be provided. Vievis Namuh Hospital), Ja-June Jang (Seoul National Univ.)
15:30-15:50	From the Quickening Period of KASL to Its Setting Sail	Young Sok Lee, Emeritus Prof. of The Catholic Univ. of Korea
15:50-16:05	Progress Toward Prevention and Control of HBV in Korea	Byung Chul Yoo, Konkuk Univ.
16:05-16:20	Progress Toward Diagnosis and Treatment of HCV in Korea	Seung Kew Yoon, The Catholic Univ. of Korea
16:20-16:35	Advance in Treatment of HCC in Korea	Kyung-Suk Suh, Seoul National Univ.
16:35-16:50	Evolution of Liver Transplantation Over Two Decades in Korea SING	E 1995 Soon Il Kim, Yonsei Univ.
16:50-17:00	KASL: 20 Years and Beyond	kwang-Hyub Han, Yonsei Univ.



DAY 2 Friday, September 11, 2015

ROOM 2

09:00-10:20	KASL & KSSCR Joint Symposium K Liver Regeneration: Where We Are Seong Gyu Hwang	g (CHA Univ.), Dongho Choi (Hanyang Univ.)
09:00-09:20	Basic Techniques: Hepatocytes and Matrix (Bioartificial Liver)	Suk-Koo Lee, Sungkyunkwan Univ.
09:20-09:40	Feasibility of Placenta-derived Stem Cells on Hepatic Failure Models	Gi Jin Kim, CHA Univ.
09:40-10:00	Adult Stem Cells: Basic to Clinical (Basic, Mesenchymal Stem Cells to Hepatocytes)	Ja Kyung Kim, Yonsei Univ.
10:00-10:20	Direct Lineage Transition by Defined Factors	Dong Wook Han, Konkuk Univ.
10:40-12:10	KLTS Coordinator Program ^(K) The Role of Coordinator in Liver Transplant Field Seung Hee Hong (Samsung Medica)	l Center), Jung Ja Hong (Asan Medical Center)
10:40-11:00	Registration and Management of the Patients on Waiting List	Kyoung Ock Jeon, Severance Hospital
11:00-11:20	Pre-transplant Education and Counseling for the Liver Recipients	Hea Seon Ha, Asan Medical Center
11:20-11:40	Post-transplant Education and Counseling for the Liver Recipients	Ji Eun Lee, Severance Hospital
11:40-12:10	Discussion	
12:10-13:30	Luncheon Symposium 4 [by MSD]	
13:30-15:00	Plenary Session 3 ^[E] Multidisciplinary Approach to Liver Cancer PART 1: Chang-Min Kim (National Cancer Center), In Seok Choi (Konyang Univ.) PART 2: Chul Ju Han (Korea Cancer Center Hospital), Kyung Sik Kim (Yonsei Univ.)	

09:00-10:20	KLTS Symposium E HCC Recurrence after Liver Transplantation Hee Jung V	Vang (Ajou Univ.), Kyung-Suk Suh (Seoul National Univ.)
09:00-09:20	Selection and Down-staging of Advanced HCC for Liver Transplantation	Francis Yao, Univ. of California San Francisco, USA
09:20-09:40	Preventive Treatment for HCC Recurrence after Liver Transplantation: Role of mTOR Inhibitor and Adjuvant Treatment	Kwang-Woong Lee, Seoul National Univ.
09:40-10:00	How to Diagnose and Manage HCC Recurrence after Liver Transplantation	Gi-Won Song, Univ. of Ulsan
10:00-10:20	Discussion	
10:40-12:10	KHBPS & KLTS Joint Symposium ^(E) Care for Long-term Survivor after Liver Tra Dong Goo Kim (nsplantation The Catholic Univ. of Korea), Soon Il Kim (Yonsei Univ.)
10:40-11:00	Post-liver Transplantation Metabolic Syndrome	Jaeseok Yang, Seoul National Univ.
11:00-11:20	Surveillance of Recurrence and De Novo Solid Tumors-De Novo Malignancies af Liver Transplantation: Incidence, Diagnosis and Treatment	ter Shin Hwang, Univ. of Ulsan
11:20-11:40	Histopathology of Allograft Dysfunction in Late Period of Liver Transplantation	Kyoung-Bun Lee, Seoul National Univ.
11:40-12:10	Allograft Dysfunction: Mechanism and Prevention	Hiroto Egawa, Tokyo Women's Medical Univ., Japan
12:10-13:30	Lucheon Symposium 5 [by Novartis]	
13:30-14:15	KHBPS & JSHBPS Joint Symposium 1 ^[E] Recent Change in the Concept and Trea Dong Wook Ci	atment in Cholangiocarcinoma hoi (Sungkyunkwan Univ.), Shin Hwang (Univ. of Ulsan)
13:30-13:45	Changing Patterns of Incidence and Treatment Strategy for Cholangiocarcinoma	Sang-Jae Park, National Cancer Center
13:45-14:00	Relationship between Recurrence Pattern of Intrahepatic Cholangiocarcinoma a (Multi-institutional Research)-Is Lymph Node Dissection Necessary?	fter Hepatic Resection and Hepatitis Virus Masaki Kaibori, Kansai Medical Univ., Japan
14:00-14:15	Update in Non-surgical Treatment in Cholangiocarcinoma	Hye Jin Choi, Yonsei Univ.





ROOM 3


_					
14:15-15:00	KHBPS & JSHBPS Joint Symposium 2 (Video Session) [E] Lessons Learned from Sung-G				o Major Hepatic Resection? Jae-Won Joh (Sungkyunkwan Univ.)
14:15-14:30	Major Hepatic Resection for Hepatobiliary Cancer with Portal Venous Involvement	ent	Kiyosł	ni Hasi	egawa, The Univ. of Tokyo, Japan
14:30-14:45	Anti-Situm In-Situ Hypothermic Perfusion Hepatectomy for Liver CA on HV	Confl	uence		Sung-Gyu Lee, Univ. of Ulsan
14:45-15:00	Surgical Challenge Beyond the Current Limit for Advanced HCC with Extensive Portal Vein Tumor Thrombosis				Yonson Ku, Kobe Univ., Japan
15:30-16:15	KHBPS & JSHBPS Joint Symposium 3 (Video Session) ^[E] Lessons Learned from Yonson K				o Donor Hepatectomy? e Chul Yu (Chonbuk Nafional Univ.)
15:30-15:45	Various Types of Donor Resection, Left Side			Куц	ıng-Suk Suh, Seoul National Univ.
15:45-16:00	Various Types of Donor Resection - Right Side Liver Graft				Hee Jung Wang, Ajou Univ.
16:00-16:15	Various Types of Donor Resection in Japan via Midline Incision			7	oru Ikegami, Kyushu Univ., Japan

ROOM 4

13:30-15:00 Plenary Session 3 ^[E] Multidisciplinary Approach to Liver Transplantation

PART 1: Yung Sang Lee (Univ. of Ulsan), Dong Goo Kim (The Catholic Univ. of Korea)

PART 2: Suk-Koo Lee (Sungkyunkwan Univ.), Young Kyoung You (The Catholic Univ. of Korea)





Program at a Glance

DAY 3 Saturday, September 12, 2015


K : Session in Korean E : Session in English

	ROOM 1	ROOM 2	ROOM 4	ROOM 5	ROOM 6	ROOM 7
08:00	* Poster Oral Presentation III (08	8:00-09:00)				
09:00	* PG: KASL Postgraduate Course					Hands-on Course:
10:00 —	PG1. Viral Hepatitis ^{IKI} (09:00-10:20)	KLCSG & KHBPS Joint Symposium ^(E) (09:00-10:20)	Free Paper 13 Cirrhosis, Liver Fibrosis (II) (09:00-10:30)	Free Paper 14 HBV (III) (09:00-10:30)	Free Paper 15 Alcoholic, Metabolic, Genetic, Immunoligic Liver Disease	Abdominal Ultrasonography (Group 1 & 2: 09:00-10:00)
-		Coffee Break (10:20-10:40)			(09:00-10:30)	Hands-on Course: Abdominal Ultrasonography (Group 3 & 4: 10:00-11:00)
11:00 —	PG2. Fatty Liver Disease (ASH & NASH) ^[K] (10:40-12:00)	KLCSG & LCSGJ Joint Symposium ^(E)	CMH Workshop ^[E] (10:40-12:00)	Korea & Mongolia Liver Symposium ⁽⁵⁾ (10:40-12:10)		Hands-on Course: Abdominal Ultrasonography
12:00 —		(10:40-12:20)		-		(Group 5 & 6: 11:00-12:00)
13:00 —	Luncheon (12:00-13:30)	KLCSG General Meeting & Luncheon Symposium 6 [by Bayer] (12:20-13:30)			Round-table Meeting ^[E&K] Can We Eradicate	
14:00 —	PG3. Changing Strategies for the Treatment of Portal Hypertension ^(K) (13:30-14:30)	Evidence Based Management of HCC ^(E) (13:30-14:50)			HCV in Korea? (12:30-14:30)	Hands-on Course: Abdominal Ultrasonography (Group 7 & 8: 13:30-14:30)
15:00 —	PG4. Practical Issues in the Management of HCC ^(K) [14:30-15:30]					Hands-on Course: Abdominal Ultrasonography (Group 9 & 10: 14:30-15:30)
16:00 —	The Liver Week 2015 Awarding & Closing Ceremony (15:30-16:00)					Hands-on Course HITACHI Supported by ALGICA
17:00 —						

The Korean Association of HBP Surgery (KHBPS)

The Korean Liver Cancer Study Group (KLCSG)

Liver Cancer Study Group of Japan (LCSGJ)





ROOM 1

Postgraduate Course: Changing Perspectives in Liver Disease

09:00-10:20	PG 1. Viral Hepatitis ^(K)	Se-Hyun Cho (The Catholic Un	iv. of Korea), Joon Hyeok Lee (Sungkyunkwan Univ.)
09:00-09:20	Next Wave of HBV Therapeutics		Ji Hoon Kim, Korea Univ.
09:20 - 09:40	DAA Pipeline and IFN-free Regimen Update		Hyung Joon Kim, Chung-Ang Univ.
09:40-10:00	What Is the Better Option for Newly Diagnosed HCV in	Korean Situation?	Chang Wook Kim, The Catholic Univ. of Kored
10:00-10:20	Management of Chronic Hepatitis B Beyond Antiviral	Agents	Gab Jin Cheon, Univ. of Ulsan
10:40-12:00	PG2. Fatty Liver Disease (ASH & NASH) (K)	Joung-II Lee (Kyung Hee	Univ.), Joon-Yeol Han (The Catholic Univ. of Korea)
0:40-11:00	Comorbidities and Long-term Outcomes of Nonalcoh	olic Fatty Liver Disease	Jeong-Hoon Lee, Seoul National Univ.
1:00-11:20	Current and Emerging Management Strategies for N	AFLD	Kang Mo Kim, Univ. of Ulsan
1:20-11:40	Diagnosis of Alcoholic Liver Disease: Invasive or Non-	·invasive?	Tae Hee Lee, Konyang Univ.
11:40-12:00	Extrahepatic Manifestations of Alcoholic Liver Disease	5	Eun Young Cho, Wonkwang Univ.
2:00-13:30	Luncheon		
13:30-14:30	PG3. Changing Strategies for the Treatment of Portal	. Hypertension ^(K) Byung-Ho Kim	(Kyung Hee Univ.), Sang-Young Han (Dong-A Univ.)
13:30-13:50	Clinical Staging of Cirrhosis and Portal Hypertension		Sung Jae Park, Inje Univ.
13:50-14:10	Carvedilol: Can It Replace Propranolol?		Chang Hyeong Lee, Catholic Univ. of Daegu
14:10-14:30	Can It Be A New Weapon Against Portal Hypertension	?	Dae Won Jun, Hanyang Univ.
4:30-15:30	PG4. Practical Issues in the Management of HCC ^{KI}	Mong Cho (Pusan Natio	nal Univ.), Sung Kyu Choi (Chonnam National Univ.)
4:30-14:50	The Prognostic Model and Risk Stratification for HCC	Development	Beom Kyung Kim, Yonsei Univ.
4:50-15:10	Decision Making of Treatment Modality of HCC: Consideration of KLCSG-NCC Korea Guideline		Bo Hyun Kim, National Cancer Center
15:10-15:30	Liver Transplantation as a Curative Treatment for HC		Bong-Wan Kim, Ajou Univ.

_		
09:00-10:20	KLCSG & KHBPS Joint Symposium (E)	Kwan Sik Lee (Yonsei Univ.), Koo Jeong Kang (Keimyung Univ.)
09:00-09:20	Optimal Selection of Surgical Candidate in Non-conventional Setting	Dong-Sik Kim, Korea Univ.
09:20-09:40	Antiviral Therapy for the Prevention of HCC Recurrence after the Surgic	cal Resection Jung II Lee, Yonsei Univ.
09:40-10:00	Surgery for HCC Patients with Portal Vein or Bile Duct Invasion	Choon Hyuck David Kwon, Sungkyunkwan Univ.
10:00-10:20	Surgical Resection versus Transcatheter Arterial Chemoembolization F Therapy for the Treatment of HCC with Segmental / Subsegmental Portal Vein Tumor Thrombus	Followed by Radiation Hee Chul Park, Sungkyunkwan Univ.
10:40-12:20	KLCSG & LCSGJ Joint Symposium ^[E] Masafos	shi Kudo (Kinki Univ., Japan), Kyung-Suk Suh (Seoul National Univ.)
10:40-10:55	HCC Nationwide Surveillance and Outcome in Korea	Young-Suk Lim, Univ. of Ulsan
10:55-11:10	HCC Nationwide Surveillance and Outcome in Japan	Masatoshi Kudo, Kinki Univ., Japan
11:10-11:25	Indication of Surgical Resection and Pre-operative Evaluation for HCC in	n Korea Nam-Joon Yi, Seoul National Univ.
11:25-11:40	Indication of Surgical Resection and Pre-operative Evaluation for HCC in	n Japan Kiyoshi Hasegawa, The Univ. of Tokyo, Japan
11:40-11:55	Advance in Transarterial Treatment: Conventional TACE	Shiro Miyayama, Fukuiken-Saiseikai Hospital, Japan
11:55-12:10	Advances in Transarterial Treatment: Drug-eluting Bead TACE	Jin Wook Chung, Seoul National Univ.
12:10-12:20	Discussion	
12:20-13:30	KLCSG General Meeting & Luncheon Symposium 6 [by Bayer]	
13:30-14:50	Evidence Based Management of HCC [E] Seung Woon Paik	k (Sungkyunkwan Univ.), Joong-Won Park (National Cancer Center)
13:30-13:50	Bridging Pathologic Information into Clinics: The Role of Liver Biopsy in Management of HCC	the Haeryoung Kim, Seoul National Univ.
13:50-14:10	Surgery vs. Locoregional Therapy for Early HCC	Su Jong Yu, Seoul National Univ.
14:10-14:30	Multimodal Treatments for Intermediate and Advanced HCC: Focused on the Non-Standard Options	Jihyun An, Univ. of Ulsan
14:30-14:50	Radiation Therapy in HCC: Implications from Korean Multicenter Regist	try Study Jinsil Seong, Yonsei Univ.

The Liver Week 2015

Scientific Program

DAY 3 Saturday, September 12, 2015

ROOM 4

10:40-12:00	CMH Editorial Board Workshop. Strategies to Improve the Journal ^[E]			Sung-Tae Hong (Seoul National Univ.)
10:40-10:50	Introduction: Selection Process for SCI			Jin-Wook Kim, Seoul National Univ.
10:50-11:05	How to Manage Editorial Board of My Journal?: Invitation, Peer Review, Edit Process, and Accept Rate Control	torial De	ecision	Samuel Lee, Univ. of Calgary, Canada
11:05-11:20	How to Manage Reviewers for My Journal: Selection, Training, Assessment	, and Re	eward	W. Ray Kim, Stanford Univ., USA
11:20-11:35	How to Manage Readers for My Journal: Communication and Citation Richard Moreau, National In	stitute foi	r Health a	nd Medical Research (INSERM), France
11:35-11:50	How to Manage Authors for My Journal: Advertisement and Invitation			Jin-Wook Kim, Seoul National Univ.
11:50-12:00	Discussion			

_		
10:40-12:10	Korea-Mongolia Liver Symposium ^(E)	
Session 1.	Do Young Kim (Yonsei Univ.), Oid	lov Baatarkhuu (Mongolian National Univ. of Medical Sciences)
10:40-10:55	Current Management of Hepatitis B, C and D Virus Infection in Mongolia	Jazag Amarsanaa, Happy Veritas Liver Diagnostic Center
10:55-11:10	New Era of Hepatitis C Management	Jun Yong Park, Yonsei Univ.
11:10-11:25	Current Status of HCC Management in Mongolia	Jigjidsuren Chinburen, National Cancer Center
Session 2.	Yun Hwan Kim (Korea U	lniv.), Jazag Amarsanaa (Happy Veritas Liver Diagnostic Center)
11:25-11:40	Management of Cirrhotic Complications, Is there Any Something New?	Sang Gyune Kim, Soonchunhyang Univ.
11:40-11:55	Epidemiology, Prevention, Control, Policy and Strategies of Viral Hepatitis in Mongolia Narangerel	Dorj, Mongolian Association for the Study of Liver Diseases
11:55-12:10	New Emerging Therapies for HCC	Yun Hwan Kim, Korea Univ.

Plenary	Session 1
PS1-1	All-Oral Dual Therapy With Daclatasvir and Asunaprevir in Patients in Korea and Taiwan With HCV Genotype 1b Infection
PS1-2	Predictors of Clinical Response: Results from a Large, Randomized Controlled Study with TDF plus PEG-IFN Combination for Chronic Hepatitis B
	Sang Hoon Ahn, Won Young Tak, Yoon Jun Kim, Young Kul Jung, Kwan Sik Lee, Jeong Heo, Si Hyun Bae, So Young Kwon, June Sung Lee, Young-Suk Lim, Seong Gyu Hwang, Soon Koo Baik, Hong Soo Kim, Nam Ik Han, Kwan Soo Byun, Lanjia Lin, Philip Dinh, Eduardo B. Martins, Patrick Marcellin
PS1-3	Nucleos(t)ide Analogues against Hepatitis B Virus Reduces the Risk of Various Major Malignancies: A Nationwide Cohort Study Based on the Health Insurance Review and Assessment Service Database 4 Dong Hyeon Lee, Jeong-Hoon Lee, Yuri Cho, Jung-Ju Yoo, Minjong Lee, Young Youn Cho, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon
PS1-4	Hepatitis B Virus Reactivation in HBsAg-negative and Anti- HBc-positive Korean Patients with Hematologic Malignancy
PS1-5	98% SVR12 in Korean and Taiwanese Patients with Chronic GT1 HCV-infection Receiving 12-weeks of Ledipasvir/Sofosbuvir: A Phase 3 Study
	Young-Suk Lim, Sang Hoon Ahn, Seung-Woon Paik, Youn-Jae Lee, Sook-Hyang Jeong, Ju-Hyun Kim, Kwan-Sik Lee, Hyung-Joon Yim, Seung-Kew Yoon, Won-Young Tak, Jia-Horng Kao, Wan-Long Chuang, Jenny C. Yang, Hongmei Mo, Bing Gao, Steven J. Knox, Phillip S. Pang, Sang-Young Han, Jeong Heo, Young-Seok Kim, Kwan-Soo Byun, Yoon-Jun Kim, Kwang-Hyub Han
PS1-6	Simeprevir plus Peginterferon/Ribavirin in Treatment-naïve East Asian Patients with HCV Genotype 1 Infection: Results from the Phase III TIGER Study
	J. Heo, L. Wei, JH Kim, KY Yoon, KS Lee, SH Um, YJ Lee, DJ Kim, SH Ahn, SK Yoon, JH Yoon, JH Shim, SW Paik, KS Byun, D Lee, R. Kalmeijer, S. Ouwerkerk-Mahadevan, O. Lenz, R. Sinha, M. Li, J. Scott, M. Peeters, J. Witek
D)	
Plenary	y Session 2
PS2-1	Differences in Prevalence, Mortality, and Patient Characteristics of Acute-on-Chronic Liver Failure Defined by APASL ACLF Research Consortium vs. EASL-CLIF Consortium
PS2-2	Acute-on Chronic Liver Failure: Is This New Entity Unrelated with Underlying Liver Disease State? ————————————————————————————————————
PS2-3	Scoring Systems Proposed for Acute-on-Chronic Liver Failure Accurately Predicts Short-term Mortality in Patients with Alcoholic Hepatitis ···· 10 Hee Yeon Kim, Tae Yeob Kim, Chang Wook Kim, Do Seon Song, Dong Hyun Sinn, Eileen L Yoon, Young Kul Jung, Heon Ju Lee, Young Seok Kim, Sang Gyune Kim, Ki Tae Suk, Dong Joon Kim
PS2-4	Investigating Immunomodulatory Role of CX3CR1 Related with Differentiation and Functional Polarization of Kupffer Cells in Alcoholic Liver Disease
	Young-Sun Lee, Ji Hoon Kim, Won-hyo Suh, Yang Jae Yoo, Tae Suk Kim, Seong Hee Kang, Sang Jun Suh, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Won-il Jeong, Kwan Soo Byun
PS2-5	RAR-Related Orphan Receptor Gamma (RORC) is a Novel Modulator of TGF-beta Pathway During Epithelial Mesenchymal Transition (EMT) Progression in Liver Fibrosis
	Sung Min Kim, Jung Eun Choi, Wonhee Hur, Jung-Hee Kim, Sung Woo Kim, Sung Woo Hong, Eun Byul Lee, Seung Kew Yoon
PS2-6	Prospective Comparison of Noninvasive Fibrosis Assessment to Predict Advanced Fibrosis or Cirrhosis in Patients with NAFLD
Plenary	y Session 3
Multidi	sciplinary Approach to Liver Cancer
PS3-01	Evaluation of Early-stage Hepatocellular Carcinoma with Magnetic Resonance Imaging Using a Liver-Specific Contrast Agent and Improvement in Survival
	Hung Don Vien Voung Cuk Lim Sounghang Han Jihuun An Ci An Vien So Voon Vien So Lung Loo Hung Lin Han Joe Ha Buun



PS3-02	The Validation of Hong Kong Liver Cancer Classification for Prediction of Survival in Patients with Hepatocellular Carcinoma in Korea: Direct Comparison with Barcelona Clinic Liver Cancer			
	Young-Sun Lee, Ji Hoon Kim, Hae Rim Kim, Yang Jae Yoo, Tae Suk Kim, Seong Hee Kang, Sang Jun Suh, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun			
PS3-03	The Pentose Phosphate Pathway (PPP) is a Novel Therapeutic Target for Hepatocellular Carcinoma (HCC) Treatment			
PS3-04	Stratification Biomarkers for Individualized Molecular Targeted Therapy in HCC			
PS3-05	The Impact of Tumor Size on Long-term Survival Outcomes after Resection of Solitary Hepatocellular Carcinoma: Single- institution Experience with 2558 Patients			
PS3-06	Phase I/lla Study of Adjuvant Immunotherapy with Tumor Antigen-pulsed Dendritic Cells in Patients with Hepatocellular Carcinoma			
Multidi	sciplinary Approach to Liver Transplantation			
PS3-07	Macro-Vascular Invasion of Hepatocellular Carcinoma Is Not an Absolute Contraindication for Living Donor Liver Transplantation			
PS3-08	Outcome of Treated Preoperative Acute Spontaneous Bacterial Peritonitis in Adult Orthotopic Liver Transplantation			
PS3-09	Occurrence and Risk Factors of Invasive Fungal Infection in Liver Transplantation Recipients (ORIGIN a multicenter study in Korea)			
PS3-10	Anti-thymocyte Globulin for Steroid Resistant Acute Rejection after Liver Transplantation			
PS3-11	Role of Endoscopic Screening for De Novo Gastric Cancer and Colorectal Cancer in Korean Liver Transplant Recipients			
PS3-12	Combined Use of Magnetic Resonance Fat Quantification and Magnetic Resonance Elastography in Living Liver Donors: Can It Reduce the Need for Preoperative Liver Biopsy? ————————————————————————————————————			
Free Pa	per Presentation			
1. HCV				
O-001	Ledipasvir/Sofosbuvir + RBV is Safe and Efficacious in Decompensated and Post Liver Transplantation HCV-infected Patients: Preliminary Results of the Prospective SOLAR-2 Trial			
O-002	Cost-Effectiveness of One-Time Screening for HCV in South Korea			
O-003	All-Oral, Fixed-Dose-Combination Therapy with Daclatasvir/ Asunaprevir/Beclabuvir, ± Ribavirin, for Chronic HCV Genotype 1-Infected Patients With Compensated Cirrhosis: Unity-2 Phase 3 Results 23 A.J. Muir, F. Poordad, J. Lalezari, G.J. Everson, G.J. Dore, P. Kwo, C. Hézode, P.J. Pockros, A. Tran, A. Ramji, R. Yang, E.A. Hughes, E.S. Swenson, P.D. Yin on behalf of the UNITY-2 Study Team			
O-004	High SVR Rates Despite Multiple Negative Predictors in Genotype 1 Patients Receiving Ombitasvir/Paritaprevir/r, Dasabuvir with/ without Ribavirin for 12/24 Weeks			
O-005	98% SVR12 in Korean and Taiwanese Patients with Chronic GT2 HCV-infection Receiving 12-weeks of Sofosbuvir + Ribavirin: An International Phase 3 Study			

O-006	Long-Term Follow-Up of Patients Treated with Daclatasvir- Based Regimens in Phase 2 and 3 Studies	
O-007	Treatment Pattern and Outcomes of Chronic Hepatitis C in South Korea Eun Sun Jang, Young Seok Kim, Kyung-Ah Kim, Youn Jae Lee, Woo Jin Chung, In Hee Kim, Byung Seok Lee, Sook-Hyang Jeong	26
O-008	GRIM19 as a Potential Modulator of Intracellular Lipid Accumulation in Hepatitis C Virus Infection	26
2. Cell	Biology / Molecular Biology	
O-009	The Role of Kruppel-like Factor 10 Deletion in Diet Induced Nonalcoholic Steatohepatitis in Mice	27
O-010	Over-expression of HNF4α Attenuated Lipotoxicity in Non- alcoholic Fatty Liver Disease Model	27
O-011	Important Role of NLRP Inflammasome Activation in Patients with Chronic Viral Hepatitis and Nonalcoholic Fatty Liver Dsease	27
O-012	MAVS and IRF3 Dependent Chemokine Production by Acute Hepatitis A Infection	28
O-013	FoxP3 and PD-1 are Decreased Significantly During 1 Year Tenofovir Therapy in Chronic Hepatitis B. Hyosun Cho, Chang Wook Kim, Ji Young Kim, Hyung Gyu Choi, Hee Yeon Kim, Jong Young Choi, Seung Kew Yoon	29
O-014	Ginsenoside Rg3 Inhibits Hepatitis C Virus Induced Aberrant Mitochondrial Dynamics: Antiviral Mechanism of Ginsenoside Rg3	
O-015	The Roles of Unphosphorylated-ISGF3 in HCV Infection and Interferon Responsiveness	29
O-016	Suppression of Neurophilin-1 Attenuates Cellular Growth and Enhances Doxorubicin-induced Cell Death in Human HCC Cells	
O-017	A Novel Adipose Derived Stem Cell Line from the Falciform Ligament of the Liver	31
3. Acu	te Liver Disease / Liver Failure / Liver Transplantation / Others]	
O-018	Prognostic Factors of Acute-on-Chronic Liver Failure in Patients with Liver Cirrhosis: the Korean Acute-on-Chronic Liver Failure (KACLiF) Studies	
	Do Seon Song, Tae Yeob Kim, Dong Joon Kim, Hee Yeon Kim, Dong Hyun Sinn, Eileen L. Yoon, Chang Wook Kim, Young Kul Jung, Ki Tae Suk, Sang Soo Lee, Chang Hyeong Lee, Hun Kim, Jeong Han Kim, Sung Eun Kim, Soon Koo Baik, Byung Seok Lee, Jae Young Jang, Jeong III Suh, Hyoung Su Kim, Seong Woo Nam, Hyeok Choon Kwon, Young Seok Kim Mo Yang, Joo Hyun Sohn, Heon Ju Lee, Seung Ha Park, Byung Hoon Han, Eun Hee Choi	Тає
O-019	The Usefulness of Simplified CLIF-SOFA and Hyponatremia for Predicting Mortality in Patients with Acute Decompensation and Chronic Liver Dise	ase
	Young Kul Jung, Tae Yeob Kim, Do Seon Song, Dong Joon Kim, Hee Yeon Kim, Dong Hyun Sinn, Eileen L Yoon, Joo Hyun Sohn, Chang Wook Kim, Ki Tae Suk, Jin Mo Yang, Heo Lee	
O-020	Characterization of Acute-on-Chronic Liver Failure and Prediction of Mortality in Patients with Severe Alcoholic Hepatitis	32
O-021	Scaffold Using Mesenchymal Stem Cell Treatment Increased Survival on Acute Liver Failure Model	33
O-022	Model to Predict Recurrence after Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond the Milan Criteria	33 Vor
O-023	A Nationwide Seroprevalence of IgG Antibody to Hepatitis A from 2010 to 2014 in Korea: age-, sex- and area-adjusted prevalence rates Kyung-Ah Kim, Moran Ki, Anna Lee, Kyoung-Ryul Lee, Sook-Hyang Jeong	33



O-024	Incidence and Clinical Features of Drug Induced Liver Injury among Government Tertiary Hospital Patients on Anti-koch's Treatment
O-025	Analysis of the Liver Volumes of Korean Adults Using Dr. Liver TM
O-026	Clinical Characteristics and Courses of Liver Abscess Caused by Toxocara
4. Live	r Cancer, Basic
O-027	Oxamic Acid Suppresses Hepatocellular Carcinoma through Amplification of ROS Production under Hypoxic Conditions
O-028	Ribosomal Association Factor NACA Is Critical for ERK Activation and Mitotic Progression in Tumor Cells
O-029	Targeting an Epigenetic Reader Reveals Novel Targets of Liver Cancer
O-030	Evolutionary Cancer Favored Engineered Vaccinia Virus Attenuates Metastatic Hepatocellular Carcinoma
O-031	Theranostics-based identification of Target Molecules for Diagnosis and Therapy in Hepatocellular Carcinoma and Cholangiocarcinoma · · · · · 36 Mi-Jin Lee, Goung-Ran Yu, Hua Lee, Yun-A Kim, Jun Zhang, Dae-Ghon Kim
O-032	Novel Genomic Marker for Predicting Prognosis in Patients with Hepatocellular Carcinoma Detected by Integration Analysis of Copy Number Alterations and Gene Expression Profile
O-033	SLC15A2 Genomic Variation Is Associated with the Extraordinary Response of Sorafenib Treatment: Whole-genome Analysis in Patients with Hepatocellular Carcinoma ————————————————————————————————————
O-034	Activation of YAP-1 by C-Myc Pathway is a Therapeutic Target in Hepatocellular Carcinoma Under Hypoxic Condition
O-035	Hypoxia Induces Myeloid-derived Suppressor Cell (MDSCs) Recruitment to Hepatocellular Carcinoma via CCL26/CX3CR1
5. Live	r Cancer, Clinical (I)
O-036	Prediction Model for the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B in the Era of Antiviral Treatment ···· 38 Jem Ma Ahn, Yeon Seok Seo, Tae Hyung Kim, Sun Young Yim, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Hong Eun Yeon, Kwan Soo Byun, Soon Ho Um
O-037	Risk Assessment of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Long-term Antiviral Therapy
O-038	Anti-platelet Therapy Reduces the Incidence of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
O-039	Increasing Incidence of and Mortality by Hepatocellular Carcinoma and Decreasing Mortality by Liver Diseases in Korea: Nationwide Whole Population Data Analyses
O-040	Hepatocellular Carcinoma in the Absence of Cirrhosis: An Etiology-based Clinicopathological Study
O-041	Long-term Outcomes of Hepatocellular Carcinoma after Curative Resection in Patients with Cirrhotic versus Non-cirrhotic Backgrounds 40 Hye Won Lee, Do Young Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Kwang-Hyub Han
O-042	Overexpression of Periostin is Related to Poor Prognosis of Hepatocellular Carcinoma ————————————————————————————————————
O-043	Expression Profile of Glypican-3 in Hepatocellular Carcinoma with Clinical Correlation

O-044 Intention-to-Treat Analysis of Various Treatment Outcomes for Hepatocellular Carcinoma Defined BCLC Stage A with Portal Hypertension · · 42 Sung Won Jung, Dong-Sik Kim, Young Dong Yu, Jae Hyun Han, Sung Ock Suh

6. Live	r Cancer, Clinical (II)
O-045	Retreatment with TACE: Transition of Model to Estimate Survival in Ambulatory Hepatocellular Carcinoma Patients Helps Decision
O-046	The Validation of a New Modified Child-Turcotte-Pugh Score Using Insulin-Growth Factor-1 as a Prognostic Model for Hepatocellular Carcinoma
	Hyeki Cho, Dong Hyeon Lee, Jeong-Hoon Lee, Yuri Cho, Jung-Ju Yoo, Minjong Lee, Young Youn Cho, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon
O-047	Optimal Staging of Single Large Hepatocellular Carcinoma ————————————————————————————————————
O-048	Survival of Hepatocellular Carcinoma Patients According to Recommended Treatment by the Barcelona Clinic Liver Cancer or Hong Kong Liver Cancer Staging System in Hepatitis B Endemic Area
O-049	Comparison of Staging Systems for the Prediction of Prognosis in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization ————————————————————————————————————
O-050	Analysis of Clinical Outcomes According to Disease Progression Pattern in BCLC-B Hepatocellular Carcinoma Patients who Received Repeated Transarterial Chemoembolization
	Jung Hee Kim, Woo Kyoung Jeong, Won Sohn, Dong Hyun Sinn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo, Yong-Han Paik
O-051	Korean Validation and Comparison of Prognostic Scores for Transarterial Chemoembolization: ART, ABCR, HAP, and Modified HAP 45 Hyun Yang, Soonkyu Lee, Hae Lim Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
O-052	Reappraisal of Portal Vein Tumor Thrombosis as a Prognostic Factor for Patients with Hepatocellular Carcinoma
O-053	Intraoperative Real-time Elastography for Differential Diagnosis of Liver Tumors ————————————————————————————————————
7. Surg	pery (I)
O-054	Clinical Implications of Segmental Gallbladder Adenomyomatosis : Single Center Experience 46 Jae Young Kim, Jae Keun Kim, Joon Seong Park, Dong Sup Yoon
O-055	Is it Fair to Routinely Insert the Drain after Laparoscopic Cholecystectomy for Acute Cholecystitis?: A Randomized Multicenter Prospective Controlled Trial
	Eun Young Kim, Tae Ho Hong
O-056	Yonsei Criteria in Minimally Invasive Surgery for Left Sided Pancreatic Cancer
O-057	Activation of Autophagy by Everolimus Confers Hepatoprotection against Hepatic Ischemia-Reperfusion Injury
O-058	Long Term Outcome after Resection of Intermediate (BCLC B) Hepatocellular Carcinoma: Comparison to Transarterial Chemoembolization
	Jun Young Kim, Dong Hyun Sinn, Gyu-Seong Choi, Jong Man Kim, Choon Hyuck David Kwon, Jae-Won Joh, Sung Wook Shin, Sung Ki Cho, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Byung Chul Yoo, Seung Woon Paik
O-059	Survival Outcome of Hepatic Epithelioid Hemangionendothelioma - A Systematic Review and an Institutional Study
O-060	Long-Term Outcome of Hepatic Resection for Combined Hepatocellular Carcinoma and Cholangiocarcinoma
O-061	False-Positive Diagnosis of Hepatocellular Carcinoma after Liver Resection



O-062	Defining Surgical Difficulty According to the Perceived Complexity of Liver Resection: Validation of a Complexity Classification in Prospective Liver Resection Cohort in Patients with Hepatocellular Carcinoma
8. HBV	/ (I)
O-063	Relationship Between Regulatory T Cells and Hepatitis B Virus-Specific Effector T Cell Responses and Its Clinical Correlation in Patients with Chronic Hepatitis B
O-064	Distribution of Quantitative HBsAg Level According to Serum HBV DNA Level in Chronic Hepatitis B; Treatment Naïve versus On-treatment
	Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Hye Jin Ku, Kwang-Hyub Han, Sang Hoon Ahn
O-065	Clinical Significance of Serum Quantitative Hepatitis B Surface Antigen Levels in Hepatitis B e-Antigen Negative Chronic Hepatitis B Patients with Elevated Hepatitis B Virus DNA Levels
O-066	A Study to Evaluate Dynamics Changes of HBsAg Quantity and its Relation with HBeAg Seroconversion Following 48 Weeks Pegylated-interferon-alpha Treatment in Patients with HBeAg Positive Chronic Hepatitis B after Long Term Nucleos(t)ide Analogue Maintenance Therapy: Interim Analyses
O-067	Pegylated-interferon Alpha Therapy for Treatment-experienced Chronic Hepatitis B Patients
O-068	Long-term Entecavir Treatment in a Large Cohort of Chronic Hepatitis B: A Prospective Real Life Data up to 8-year Follow-up
O-069	Long Term Clinical Outcome in Chronic Hepatitis B Patients with Partial Virologic Response to Entecavir Treatment
O-070	Quality of Life among Korean Patients with Chronic Hepatitis B
O-071	Assessing Dietary Status in Korean Patients with Chronic Hepatitis B
9. HBV	/ (II)
O-072	Randomized Comparison of Tenoforvir versus Entecavir plus Adefovir in Suboptimal Responder for Lamivudine-adefovir Therapy in Patients with rt204I/V Mutation
	Sae Hwan Lee, Hong Soo Kim, Sang Gyune Kim, Young Seok Kim, Dae Won Jun, Young Don Kim, Gab Jin Cheon, Tae Yeob Kim, Joo Hyun Sohn, Byung Seok Lee, Soung Won Jeong, Jae Young Jang, Boo Sung Kim
O-073	Tenofovir Monotherapy vs Tenofovir and Entecavir Combination Therapy in Adefovir-Resistant Chronic Hepatitis B Patients with Multiple Drug Failure: 96-Weeks Results of a Randomized Trial
O-074	Comparing Antiviral Efficacy of Tenofovir Monotherapy and Tenofovir Based Combination Therapy in Antiviral Resistant Chronic Hepatitis B: An Interim Result of Multicenter Cohort Study
O-075	The Analysis of Efficacy and its Influencing Factors of Tenofovir Based-rescue Therapy in Chronic Hepatitis B Patients According to Genotypic Resistant Mutation to Various Drugs
O-076	Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(t)ide Analogue-experienced Chronic Hepatitis B Patients
O-077	Comparison of Early Virologic Response between Entecavir and Tenofovir in Chronic Hepatitis B: A Propensity Score Matching Analysis 56 Jung Wha Chung, Won Keun Si, Joo Yeong Baeg, Junhyeon Cho, Eun Sun Jang, Sook-Hyang Jeong, Jin-Wook Kim
O-078	Long Term Follow Up of Chronic Hepatitis B Patients after Oral Antiviral Treatment Discontinuation

O-079 Discontinuation of Antiviral Prophylaxis in Hepatitis B Virus Infected Patients Who Received Cytotoxic Chemotherapy: Outcomes and Predictors 56 Kyung Sook Lim, Hyo Jin Kim, Jung Hee Kim, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chui 10. Cirrhosis / Liver Fibrosis (I) Jae Yoon Jeong, Dae Won Jun, Ho Soon Choi, Byung Chul Yoon, Joo hyun Sohn, Chang Hong Lee, Oh Young Lee, Kang Nyeong Lee, Hang Lak Lee Clinical Impact of Subclinical Ascites in HBV-related Cirrhotic Patients Treated with Antiviral Treatment 57 Sun Young Yim, Hongkeun Ahn, Jeong-Hoon Lee, Seung Up Kim, Sang Gyune Kim, Young Seok Kim, Jeong Han Kim, Won Hyeok Choe, Tae Yeob Kim, Young Kul Jung, Sang Jun Suh, Ki Tae Suk, Hyunggin An, Yeon Seok Seo, Soon Ho Um Risk Assessment of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B Starting Antiviral Therapy: Transient Elastography O-082 Mi Na Kim, Yeon Seok Seo, Seung Up Kim, Sang Gyune Kim, Soon Ho Um, Kwang-Hyub Han, Young Seok Kim O-083 Adjusting the Fibrotic Burden Using Transient Elastography Reveals Similar Long-term Outcomes in Chronic Hepatitis B Patients Treated with Hye Soo Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han Yan Wang, Oian-Jin Feng, Jin-Lin Hou Joon Ho Lee, Sung Woo Hong, Wonhee Hur, Jung-Hee Kim, Jung Eun Choi, Sung Min Kim, Eun Byul Lee, Seung Kew Yoon 0-086 Liver Stiffness Measured by Magnetic Resonance Elastography is not Associated with Recurrence after Curative Treatment of Hepatocellular Young Youn Cho, Dong Hyeon Lee, Jeong-Hoon Lee, Dong Ho Lee, Ju Hyeon Jeon, Jeong Min Lee, Joon Koo Han, Hongkeun Ahn, Hyeki Cho, Jung-Ju Yoo, Minjong Lee, Yuri Cho, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jung Min Lee, Jung-Hwan Yoon 11. Liver Cancer, Clinical (III) O-087 Surgical Treatment for Early Stage HCC in Transplantation Era 60 Hee Jung Wang, Bong Wan Kim, Young Keun Park Eui Joo Kim, Yun Soo Kim, Joo Il Kim, Seung Kak Shin, Oh Sang Kwon, Duck Joo Choi, Ju Hyun Kim O-089 Validity of Barcelona Clinic Liver Cancer Stage A: Association of Tumor Size and Overall Survival in a Single Hepatocellular Carcinoma 61 Yeonjung Ha, Mi Jung Jun, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee O-090 Combining Transarterial Chemoembolization with Radiofrequency Ablation versus Hepatic Resection by Using Propensity Score Matching in Young Kul Jung, Joo Hee Park, Sang Jun Suh, Hyung Joon Yim, Oh Sang Kwon, Yun Soo Kim, Duck Joo Choi, Ju Hyun Kim, Ji Hoon Kim, Jong Eun Yeon, Kwan soo Byun, Yeon Seok Seo, Soon Ho Um. Ho Sang Ryu O-091 Multi-analyte Analysis of Serum Cytokines to Predict Treatment Outcome in Patients with Hepatocellular Carcinoma Treated with Radiotherapy ------62 Hyejung Cha, Eun Jung Lee, Jinsil Seong O-092 Comparing Treatment Outcomes between Radioembolization Using Yttrium-90 Microspheres and Concurrent Chemoradiation Therapy for Locally Mi Yeon Kim, Kyu Sik Jung, Do Young Kim, Jinsil Seong, Jong Yun Won, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Kwang-Hyub Han Sang Il Choi, Ami Yu, Bo Hyun Kim, Eun Jung Ko, Sun Seob Park, Byung Ho Nam, Joong-Won Park O-094 Estimation of Survival after Stopping Sorafenib in Patients with Advanced Hepatocellular Carcinoma: Development and Validation of the Hyun Soo Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han



12. Su	rgery (II)
O-095	The Hypoxic Conditioned Secretome from Human Adipose- derived Stem Cells Improves Mouse Liver Regenerative Potential through the Suppression of SOCS3
O-096	Outcome of Living Donor Liver Transplantation Using Partial Liver Allografts with Dual Arterial Supply ———————————————————————————————————
O-097	Outcomes and Recurrence Patterns after Non Anatomic Liver Resection for Solitary HCC Hun Tak Ha, Jae Min Chun, Yoon Jin Hwang, Young Seok Han
O-098	Analysis of Risk Factors for Post-hepatectomy Thrombosis
O-099	Which is the Predictable Value of Post-transplant HCC Recurrence between Tumor-related Factors at the Initial Diagnosis and the Transplantation?
	Jae Geun Lee, Juhan Lee, Jung Jun Lee, Myoung Soo Kim, Man Ki Ju, Gi Hong Choi, Jin Sub Choi, Soon II Kim, Dong Jin Joo
O-100	Laparoscopic Caudate Lobectomy
O-101	Conjoined Unification Venoplasty for Graft Double Portal Vein Branches as a Modification of Autologous Y-graft Interposition
O-102	Clinical Analysis of Recurrent Hepatocellular Carcinoma after Living Donor Liver Transplantation
O-103	Alterations of Hepatocellular Bile Salt Transporters and Effects of Immunosuppressants after Warm Ischemic Injury in Rats
13. Cir	rhosis / Liver Fibrosis (II)
O-104	Systematic Analysis Reveals Cromolyn Sodium as Anti-fibrotic Agent to Target Both Hepatocytes and Hepatic Stellate Cells
O-105	The Association between the Hepatic Venous Pressure Gradient and Portosystemic Collateral Vessels in Portal Hypertension and its Complications
	Won Young Park, Soung Won Jeong, Jae Young Jang, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim, Yong Jae Kim, Suyeon Park, Young Ok Kim
O-106	The Association between the Grade and Frequency of Thoracic Duct Dilatation with Portal Hypertension and Variables in Advanced Liver Cirrhosis
	Seung Woon Park, Soo Youn Ham, Sun Young Yim, Tae Hyung Kim, Jemma Ahn, Han Ah Lee, Soon Ho Um, Yeon Seok Seo, Yoon Tae Jeen, Hong Sik Lee, Hoon Jai Chun, Chang Duck Kim, Ho Sang Ryu, Eun Sun Kim, Bora Keum
O-107	Urine Cystatin C is a Strong Predictor for Short-term Mortality and Therapeutic Response to Terlipressin in Cirrhotic Patients with Serum Creatinine Greater than 1.5mg/dl 69
	Sang Gyune Kim, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Sae Hwan Lee, Hong Soo Kim, Young Don Kim, Gab Jin Cheon, Boo Sung Kim
O-108	A New Prognostic Model for 1-year Mortality in Patients with Decompensated Heaptits B Virus-related Liver Cirrhosis Receiving Antiviral Treatment 70
	Tae Hyung Kim, Dae Hoe Gu, Soon Ho Um, Seok Bae Yoon, Tae Jung Yun, Sun Young Yim, Jin Young Jung, Yeon Seok Seo, Hyung Joon Yim, Bora Keum, Yoon Tae Jeen, Hong Sik Lee, Hoon Jai Chun, Chang Duck Kim, Ho Sang Ryu
O-109	Change of the Causative Factors of Liver Cirrhotic Patients in Daegu-Gyeongbuk Province during Recent 15 Years
O-110	Outcomes of Patients Who Treated with Sengstaken-Blakemore Tube for Uncontrolled Variceal Hemorrhage
0-111	Liver Cirrhosis and Cancer: Comparison of Mortality

0-112	Liver Disease and Cancer: Comparison of Economic Burden	71
	Wankyo Chung, Changik Jo, Woo Jin Chung, Dong Joon Kim	
14. HE	3V (III)	
O-113	Hepatitis B Virus Reactivation in HBsAg-negative and Anti-HBc-positive Patients Undergoing Rituximab-based Chemotherapy for Lymphoma	
	Yuri Cho, Su Jong Yu, Dong Hyeon Lee, Minjong Lee, Jeong-ju Yoo, Young Youn Cho, Eun Ju Cho, Jeong-Hoon Lee, Tae Min Kim, Dae Seog Heo, Yoon Jun Kim, Jung-Hwan Yoo	, _
0-114	Prepartum Use of Telbivudine on Preventing Mother-to-Child Transmission of Hepatitis B Virus: A Prospective Non-Randomized Open-Labeled	d
	Multi-Center Study Chung-Hwa Park, In-Yang Park, Juyoung Lee, Sang Bong Ahn, Jung Hwan Shin, Young Min Ahn, Hyun Seung Lee, Sa-Jin Kim, U Im Chang, Chang Wook Kim, Se Hyun Jo, Young L Jong-Hyun Kim, Si Hyun Bae, Mother-to-Child Transmission of Hepatitis B Prevention Working Group	
O-115	A Randomized Trial Evaluating the Antiviral Efficacy of Switching from Lamivudine Plus Adefovir to Tenofovir Monotherapy in Lamivudine-resista Chronic Hepatitis B Patients with Undetectable Hepatitis B Virus DNA - The 48 week Interim Analysis	73
O-116	Association between HBeAg Seroconversion and Risk of Hepatocellular Association between HBeAg Seroconversion and Risk of Hepatocellular Carcinoma during Treatment with Lamivudine or Entecavir for Chronic Hepatitis B Jihyun An, Young-Suk Lim, Hwa Jung Kim, Hyung-Don Kim, Gi-Ae Kim	ar 73
O-117	Entecavir and Tenofovir More Effectively Reduce the Recurrence of Hepatitis B Virus-related Hepatocellular Carcinoma after Curative Treatment	eni
	than Low-potent Antivirals	
O-118	Risk of Hepatocellular Carcinoma and Mortality among Treated Patients with Chronic Hepatitis B vs Chronic Hepatitis C Gi-Ae Kim, Young-Suk Lim	74
O-119	Prevalence and Significance of Occult Hepatitis B Virus Infection in Chronic Hepatitis C in South Korea	74
O-120	Long-term Outcome in Chronic Hepatitis B Patients with HBsAg Seroclearance	75
O-121	Clinical Outcome of Long-term Entecavir Therapy in Patients with Compensated and Decompensated Cirrhosis: Benefit for Reversal of Cirrho)SİS
	Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Hye Jin Ku, Kwang-Hyub Han, Sang Hoon Ahn	/_
15. Al	coholic / Metabolic / Genetic / Immunologic Liver Disease	
O-122	Intrahepatic Fat Distribution and Variability According to Multiple-Echo Dixon Technique in Patients with Liver Disease	75
O-123	Reverse Correlation with FXR Expression of Peripheral Mononuclear Cell and NPC1L1 Expression of Terminal Ileum in Non-alcoholic Fatty Liver Disease	3SE
	Sang Bong Ahn, Dae Won Jun, Kiseok Jang, Byoung Kwan Son, Jae Yoon Jeong, Joo Hyun Sohn, Chang Hong Lee	/0
O-124	Aronia Melanocarpa Extract Ameliorates Hepatic Lipid Metabolism through PPARγ2 Downregulation ······ Chung-Hwa Park, Jung-Hee Kim, Eun Byul Lee, Wonhee Hur, Hyoung-Jin Park, Seung Kew Yoon	76
O-125	Prevalence and Predictors of Significant Liver Fibrosis among Subjects with Transient Elastography-defined Nonalcoholic Fatty Liver Disease	70
	Hye Won Lee, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han	/6
O-126	A Prospective Comparative Study to Assess the Accuracy of Fibroscan in Evaluating Liver Steatosis	
O-127	Assessment of Risk Factors in Patient with Non-obese and Obese Non-alcoholic Fatty Liver Disease	
O-128	Demographic, Lifestyle, Medical and Familial Factors Associated with Primary Biliary Cirrhosis in Korea	77



O-129 Nationwide, Population-based Prevalence, Complications, Comorbidity and Medical cost of Primary Biliary Cirrhosis in South Korea, 2009-2013 78 Kyung-Ah Kim, Moran Ki, Hwa Youg Choi, Bo Hyun Kim, Eun Sun Jang, Sook-Hyang Jeong Bossng Kang, Chae-Young Bang, Se-Young Choung, Kyungwoo Choi **Poster Oral Presentation** HBV (I) Tae Suk Kim, Ji Hoon Kim, Young-Sun Lee, Yang Jae Yoo, Seong Hee Kang, Sang-June Suh, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun PO-002 Prolonged Entecavir Therapy Improves Liver Fibrosis Estimated by APRI in Majority of Naïve Patients with a Partial Virological Response 83 Hee Yeon Kim, Chang Wook Kim, Hyung Gyu Choi, Ji Young Kim, Chang Don Lee, Seung Kew Yoon, Jong Young Choi, Si Hyun Bae, Yoo Dong Won, Soo Lim Lee PO-003 Efficacy of Continuous Tenofovir Monotherapy for Partial Virologic Response to Tenofovir in Treatment-Naïve Chronic Hepatitis B Patients · · 83 Min Keun Kim, Sun Mi Kang, Si Hye Kim, Jeung Eun Song, Ga Young Kim, Sang Ah Baek, Chang Hyeong Lee, Byung Seok Kim PO-004 Tenofovir and Entecavir has Similar Renal Adverse Events on Hepatocelluar Carcinoma Patients Treated with Transarterial Chemoembolization Young Youn Cho, Su Jong Yu, Jung-Ju Yoo, Minjong Lee, Dong Hyeon Lee, Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Yoon Jun Kim, Jung-Hwan Yoon PO-005 Renal Tubular Dysfunction of Prophylactic Treatment with Anti-hepatitis B Immunoglobulin Combined Lamivudine and Adefovir Dipivoxil in Liver Jae Geun Lee, Juhan Lee, Jung Jun Lee, Seung Hwan Song, Man Ki Ju, Gi Hong Choi, Myoung Soo Kim, Jin Sub Choi, Soon Il Kim, Dong Jin Joo HBV (II) Jung Hee Kim, Dong Hyun Sinn, Kyunga Kim, Hyeseung Kim, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul PO-007 Usefulness of Transient Elastography in Evaluation of Antiviral Effect with Oral Nucleos(t)ides in Patients with Chronic Hepatitis B Virus (HBV) Infection Angelo Lozada, Hae Lim Lee, Hyun Yang, Soonkyu Lee, Si Hyun Bae, Seung Kew Yoon Young Woon Kim, Jung Hyun Kwon, Jeong Won Jang, Sung Won Lee, Soon Woo Nam, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon Won Keun Si, Jung Wha Chung, Jun Hyeon Cho, Joo Yeong Baeg, Sook-Hyang Jeong, Eun Sun Jang, Jin-Wook Kim Limuel Anthony B. Abrogena PO-011 Prevalence and Risk Factors of Hepatitis B Infection in Pregnant Women at the Prenatal Clinic of the Philippine General Hospital87 Gian Carlo Carpio, Aubrey Taguba, Lana Tan Cell Biology / Molecular Biology PO-012 Establishment of Cell-to-Cell in Silico Network Model based on Transcriptome Profiles of Various Types of Cells during the Process of Liver Fibrosis Jung Eun Choi, Wonhee Hur, Jung-Hee Kim, Sung Woo Kim, Sung Woo Hong, Eun Byul Lee, Sung Min Kim, Joon Ho Lee, Daehee Hwang, Seung Kew Yoon Yejoo Jeon, Yoon Suk Choi, Eun Sun Jang, Jin Wook Kim, Sook-Hyang Jeong Jeong-Ju Yoo, Jung-Hwan Yoon, Dong Hyeon Lee, Yuri Cho, Yun Bin Lee, Minjong Lee, Young Youn Cho, Won-mook Choi, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Chung Yong Kim, PO-015 Inactivating Mechanism of ATBF1 Gene In Hepatocellular Carcinomas 88 Chang Jae Kim, Jung Woo Shin, Seok Won Jung, Bo Ryung Park, Neung Hwa Park

PO-016	Ideal Sphere Forming Culture Condition to Maintain the Stemness in Hepatocellular Carcinoma Cell Line
PO-017	Inhibition of Hepatic Stellate Cells by Bone Marrow-derived Mesenchymal Stem Cells in Hepatic Fibrosis
Cirrhos	sis / Liver Fibrosis (I)
PO-018	Noradrenaline vs Terlipressin for Hepatorenal Syndrome (No to Hepatorenal Syndrome): A Meta Analysis
PO-019	Validation of Relationship between Variation in the Promoter Region of Glutaminase Gene and Development of Hepatic Encephalopathy in East Asian
	Jem Ma Ahn, Soon Ho Um, Han Ah Lee, Seung Woon Park, Chang Ho Jung, Tae Hyung Kim, Sun Young Yim, Chang Ha Kim, Hyuk Soon Choi, Eun Sun Kim, Bora Keum, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Yoon Tae Jeen, Jong Eun Yeon, Hong Sik Lee, Hoon Jai Chun, Kwan Soo Byun, Chang Duck Kim, Ho Sang Ryu
PO-020	A Family with Four Siblings Affected with Primary Biliary Cirrhosis
PO-021	A Retrospective Study on Noninvasive Predictors of Esophageal Varices In Patients with Liver Cirrhosis, a Makati Medical Center Experience · 91 Gabriel Romualdo L. Valero, Ernesto Olympia
PO-022	Blood Urea Nitrogen to Creatinine Ratio Reflects Current Variceal Bleeding in Patient with Liver Cirrhosis
PO-023	Low Baseline Serum Creatinine and Small Increase in Creatinine Predict Mortality in Cirrhotic Patients with Ascites
Alcoho	olic / Metabolic / Genetic / Immunologic Liver Disease
PO-024	Genetic Polymorphism Associated with the Development of Metabolic Syndrome and Non Alcoholic Fatty Liver Disease
PO-025	Nonalcoholic Fatty Liver Disease (NAFLD) among Adult Patients with Type 1 Diabetes Mellitus: Prevalence and Association with Metabolic Syndrome and Cardiovascular Diseases —————————————————————————————————
PO-026	Efficacy of Supplementation with Vitamin B6, Vitamin B12, and Folate in Patients with Alcoholic Liver Disease 93 SY Ko, JH Kim, WH Choe, SY Kwon, HS Ahn, KP Kim, HB Chae
PO-027	Prevalence, Treatment Pattern and Healthcare-related Costs of Wilson's Disease Using National Health Insurance Data from 2009-2013, South Korea
	Eun Sun Jang, Hwa Young Choi, Moran Ki, Bo Hyun Kim, Kyung-Ah Kim, Sook-Hyang Jeong
PO-028	Utility of Thromboelastography and Comparing with Traditional Coagulation Tests in Assessing the Risk of Bleeding and Thrombosis in Cirrhotics
	Vaibhav Somani, Apurva Shah, Deepak Amarapurkar
PO-029	Gilbert Syndrome in an Adolescent Male with Co-existing Glucose-6-phosphate Dehydrogenase Deficiency: A Case Report
Liver C	aner, Clinical (I)
PO-030	Hepatocellular Carcinoma Risk in Chronic Hepatitis B Virus- infected Compensated Cirrhosis Patients with Low Viral Load
PO-031	Influence of Hepatitis B Virus DNA Elevation on Recurrence of Hepatocellular Carcinoma after Surgical Resection and the Preventive Role of Antiviral Therapy 95
	Yang Jae Yoo, Ji Hoon Kim, Young Sun Lee, Tae Suk Kim, Sung Hee Kang, Sang Jun Suh, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun
PO-032	Anti-HBe Positivity is Protective for HCC Development in Naïve Hepatitis B Viral Cirrhotic Patients Treated with Long-term Entecavir Monotherapy
	Fun Sun Jang Jong Ho Lee Seong Min Chung Jin-Wook Kim Sook-Hyang Jeong



PO-033	Serum Interleukin-6 Levels as a Predictive Marker of Recurrence in Patients with Hepatocellular Carcinoma Who Underwent Curative Treatment
	Hyo Jung Cho, Soon Sun Kim, Joo Han Park, Choong Kyun Noh, Jae Youn Cheong, Sung Won Cho
PO-034	Risk of Secondary Cancer after Diagnostic Radiation Exposure in Patients with Hepatocellular Carcinoma: A Big Data Analysis
Surgery	r. Liver (I)
PO-035	Prognostic Impact of Tumor Growth Type on 7th AJCC Staging System for Intrahepatic Cholangiocarcinoma: A Single-center Experience of 659
	Cases Shin Hwang, Young-Joo Lee, Gi-Won Song, Kwang-Min Park, Ki-Hun Kim, Chul-Soo Ahn, Deok-Bog Moon, Sung-Gyu Lee
PO-036	Safety and Feasiblity of Laparoscopic Major Hepatectomy (LMH) Post Portal Vein Embolization (PVE), A Case Series
PO-037	Isolated Caudate Lobectomy for Solitary Hepatocellular Carcinoma: Single-institution Experience with 33 Patients
PO-038	Effective Management of Male Primary Hepatic Choriocarcinoma: A Case Report and Literature Review
PO-039	Significance of Complete Anatomical Resection for Hepatocellular Carcinoma: A Case Report
PO-040	Damage Control Surgery for Liver Laceration with Major Vessel Injury: Vascular Control Followed by Delayed Hepatectomy
Surgery	t. Liver (II)
PO-041	Locoregional Therapy in Patients with Hepatocellular Carcinoma: A Real Life Experience 99 Pratibha Sonawane, Deepak Amarapurkar
PO-042	Prediction of Post-hepatectomy Liver Insufficiency Using Liver Stiffness Measurement for the Patient with Hepatocellular Carcinoma
PO-043	Technical Advance to Prevent Hepatic Outflow Disturbance in Right Lobe Living Donor Liver Transplantation? : New Simplified One-orifice Venoplasty
	Joo Dong Kim, Dong Lak Choi
PO-044	Surgical Outcome of Laparoscopic Major Liver Resection - A Large Volume Center's 10 Years' Experience
PO-045	Synergistic Anticancer Effect of Metformin in Combination with Immunosuppressant on Hepatocellular Carcinoma Cell Lines
PO-046	Laparoscopic Right-sided Major Hepatectomy: Toward a Protocolization and Simplification
Surgery	r. Transplantation
PO-047	Outcomes of Living and Deceased Donor Liver Transplant Recipients according to The MELD score
PO-048	Outcomes and Survival: A Single Center Analysis of Liver Transplantation Program
PO-049	Results of ABO Incompatible Liver Transplantation Using a Simplified Protocol at a Single Institution
PO-050	Outcomes of Simultaneous Major Liver Resection and Colorectal Surgery for Colorectal Liver Metastases

Surgery	y: Pancreas & Biliary	
PO-051	Oncologic Impact of Monocarboxylate Transporter 4 (MCT4) in Pancreatic Cancer	103
PO-052	Comparison of the Prognosis of Endoscopic Retrograde Cholangiopancreatography Between Patients with Liver Cirrhosis vs Non-cirrhosis · Jae Min Lee, Hong Sik Lee, Jong Jin Hyun, Tae Hyung Kim, Jem Ma Ahn, Sun Young Yim, Yeon Seok Seo, Soon Ho Um, Chang Duck Kim, Ho Sang Ryu	103
PO-053	Life-threatening Hemobilia from a Ruptured Gastroduodenal Artery Pseudoaneurysm after Cholecystectomy: A Case Report	104
PO-054	Intradutal Tubulopapillary Neoplasm of the Pancreas with an Associated Invasive Carcinoma	104
PO-055	Preoperative Volume-based PET Parameter, MTV2.5, As a Potential Surrogate Marker for Tumor Biology and Recurrence in Resected Pancreatic Ca	
	Sung Hwan Lee, Chang Moo Kang, Ho Kyoung Hwang, Sung Hoon Choi, Mi Jin Yun, Woo Jung Lee	104
PO-056	Living Donor Liver Transplantation for Diffuse Biliary Papillomatosis	105
HBV (III		
PO-057	Baseline Quantitative HBsAg Level is Predictive of Virologic Response in Entecavir Treated Patients	105
PO-058	Quantitative Hepatitis B Surface Antigen and Hepatitis B Virus DNA Levels for Predicting Treatment Response to Tenofovir Therapy in Chronic Hepatitis B	105
PO-059	Kinetics of Serum Hepatitis B Surface Antigen During the First Year of Tenofovir Treatment in Patients with Chronic Hepatitis B	106
PO-060	Expressions of Hepatocyte HBcAg and HBsAg as a Marker in the Management of Chronic Hepatitis B Patients	
PO-061	Comparison of Efficacy between Tenofovir and Entecavir in Treatment Naive Chronic Hepatitis B Patients	108
PO-062	Comparison of Tenofovir-based Therapy versus Lamivudine Plus Adefovir Combination Therapy in Patients with Lamivudine-Resistant Chror Hepatitis B: Propensity Score Analysis	nic 108
	Mu-yeol Lee, Jung Woo Shin, Sungsoo Byun, Bo Ryung Park, Min-Ho Kim, Chang Jae Kim, Byung Uk Lee, Jae Ho Park, Byung Gyu Kim, Seok Won Jung, In Du Jeong, Sung-Jo Bang, N Hwa Park	leung
HCV		
PO-063	All-Oral Dual Combination of Daclatasvir Plus Asunaprevir Compared with Telaprevir Plus Peginterferon-Alfa/Ribavirin in Chronic HCV Genotable Infected Treatment-Naive Japanese Patients Y. Karino, F. Suzuki, Y. Suzuki, J. Toyota, K. Chayama, Y. Kawakami, S. Fujiyama, T. Ito, Y. Itoh, E. Tamura, T. Ueki, H. Ishikawa, M. Linaberry, E.A. Hughes, H. Kumada	
PO-064	Elderly and Cirrhotic Patients without Baseline NS5A Polymorphisms In HCV Genotype 1b Have Very High SVR to Daclatasvir Plus Asunapre	vir
	F. McPhee, Y. Suzuki, J. Toyota, Y. Karino, K. Chayama, Y. Kawakami, H. Ishikawa, R. Bhore, N. Zhou, D. Hernandez, P. Mendez, H. Kumada	109
PO-065	All-Oral, Fixed-Dose Combination Therapy with Daclatasvir/ Asunaprevir/Beclabuvir for Patients with Chronic HCV Genotype 1 Infection with Cirrhosis: Unity-1 Phase 3 Results	110
PO-066	Direct Medical Cost for Hepatitis C Virus Infection in South Korea, 2009-2013 ····· Moran Ki, Hwa Young Choi, Eun Sun Jang, Sook-Hyang Jeong	110
PO-067	Acute Hepatitis and Reactivation of Hepatitis C Virus in Cancer Patients Receiving Systemic Chemotherapy	110



PO-068	Genotype-Dependent Regulation of HCV Replication by Host Kinases	· 111
Cirrhos	sis / Liver Fibrosis (II)	
PO-069	Change of Fibrosis Pattern after Autologous Bone Marrow Cell Infusion in Patients with Advanced Liver Cirrhosis	· 111
PO-070	Expression of S100B During Hepatofibrogenesis by Bile Duct Ligation in C57BL/6mice	· 112
PO-071	The Role of Beclin 1 During Epithelial Mesenchymal Transition in Liver Fibrosis	· 112
PO-072	Essential Roles of Focal Adhesion Kinases (FAK and PYK2) in TGF-β-mediated Fibrogenic Signaling in Hepatic Stellate Cell	· 112
PO-073	Sub-cirrhotic Range of Liver Stiffness Assessed Using Transient Elastography is Associated with a Decreased Risk of Hepatocellular Carcinoma Ar Patients with HBV-related Cirrhosis	mong ·· 113
	Mi Young Jeon, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han	
PO-074	Both Elevation of Hepatic Venous Pressure Gradient and Liver Stiffness can predict the Poor Long-term Mortality in Non-critically ill Patients	
	Jae Yoon Jeong, Sun Min Kim, Tae Yeob Kim, Joo Hyun Sohn, Ji Yeoun Kim, Yongsoo Kim, Jinoo Kim, Woo Kyoung Jeong	
Liver T	ransplantation / Others (I)	
PO-075	The Model for Predicting Survival after Liver Transplantation	· 113
PO-076	ABO Incompatible Living Donor Liver Transplantation Using Rituximab without Antibody Removal	· 114
PO-077	Efficacy and Safety of Prophylaxis with Entecavir or Tenofovir and Hepatitis B Immunoglobulin in Preventing Hepatitis B Recurrence after L	iver
	Transplantation	. 114
PO-078	Combination of Pegylated-interferon and Ribavirin as a Treatment after Liver Transplantation for Recurrent Hepatitis C virus: Single Center Experwith High Virological Response	ience
	Young Mi Hong, Ki Tae Yoon, Mong Cho, Dae Hwan Kang, Hyung Wook Kim, Cheol Woong Choi, Su Bum Park, Jeong Heo, Hyun Young Woo, Won Lim	. 114
PO-079	A Rare Infectious Complication after LDLT; Pyogenic Spondylodiscitis Casued by Methicillin-resistant Staphylococcus aureus (MRSA)	· 115
PO-080	Appearance and Clinical Characteristics of Contrast Enhanced Ultrasonography in Pyogenic Liver Abscess	· 115
PO-081	Plasma Cell Hepatitis following Liver Transplantation	· 116
Liver Ti	ransplantation / Others (II)	
PO-082	RIP1 and RIP3 Inhibition Aggravates Hepatic Ischemic Reperfusion Injury	· 116
PO-083	Effect of G-CSF on Mouse Hepatic Ischemic Reperfusion Injury Model	· 116
PO-084	Long Term Follow-up of Budd Chiari Patients Undergoing TIPS	· 117
PO-085	Hepatectomy for Primary Hepatolithiasis ······ Hirak Pahari, Wei-Feng Li, Chih-Chi Wang, Ting-Lung Lin, Shih-Ho Wang, Chih-Che Lin, Yueh-Wei Liu, Chee-Chien Yong, Tsan-Shiun Lin, Allan M. Concejero, Chao-Long Che	
PO-086	Depression and Self-Care Compliance in Patients with Chronic Hepatic Disease	

Liver C	ancer, Clinical (II)	
PO-087	Correlation of MR and Pathologic Findings of the Indeterminate Small (≤ 3 cm) Hepatic Lesions in Chronic Liver Disease	18
PO-088	Survival Analysis of Re-hepatectomy Versus Re-radiofrequency Ablation for Intrahepatic Recurrence after Initial Hepatectomy or Radiofrequency Ablation for Hepatocellular Carcinoma	18
PO-089	Optimal Interval Between On-demand Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma	19
PO-090	Prognostic Factors for Complete Response and Recurrence after Transarterial Chemoembolization in Hepatocellular Carcinoma	
PO-091	Transarterial Chemoembolization Contributed Survival Gain Following Combined Chemoradiation Therapy for Advanced Hepatocellular Carcinor	
	Ja Kyung Kim, Jung Il Lee, Jun Won Kim, Ik Jae Lee, Seung-Moon Joo, Kwang Hoon Lee, Eun Suk Cho, Tae Joo Jeon, Kwan Sik Lee	20
Liver Ca	ancer, Basic (I)	
PO-092	ACT Promotes Hepatocellular Carcinoma Growth and Metastasis through the mTORC1 and β-Catenin Signaling Pathways	20
PO-093	Attenuation of Liver Tumor Initiating Cells Reduces Migration and Metastasis via Regulation of ELK3/Net Expression	20
PO-094	Mechanism of Synergistic Effect of Sorafenib and Celecoxib on Inducing Apoptosis in Hepatocellular Carcinoma Cell PLC/PRF/5	21
PO-095	Emodin Enhanced Radiation Killing Effect of Hepatocellular Carcinoma in Vitro and in Vivo	21
PO-096	Plasma MicoRNA-122 Level as a Predictive Marker for Treatment Response After Transarterial Chemoembolization in Patients with Hepatocellul Carcinoma Soon Sun Kim, Hyo Jung Cho, Ji Sun Nam, Joo Han Park, Choong Kyun Noh, Je Hwan Won, Jae Ik Bae, Sung Won Cho, Jae Youn Cheong	lar 22
PO-097	Double Primary Intrahepatic Cholangiocarcinoma and Adrenal Metastases of Hepatocellular Carcinoma: A Case Report	22
Liver Ca	ancer, Basic (II)	
PO-098	Filamin B Acts as a Tumor Suppressor for Hepatocellular Carcinoma in Hypoxic Conditions by Activating the JNK Pathway	22
PO-099	Role of Bile Acid-induced Fibroblast Growth Factor 19 Expression in Hepatocellular Carcinoma Proliferation	23
PO-100	Correlation Analysis of Discoidin Domain Receptor 2 Expression and Prognosis of Hepatocellular Carcinoma after Surgical Resection	23
PO-101	S100A8/9 Overexpression by the JNK Pathway is Involved in Inflammation-associated Hepatocarcinogenesis Under Hypoxic Conditions 12 Yuri Cho, Hyeki Cho, Dong Hyeon Lee, Minjong Lee, Jeong-ju Yoo, Young Youn Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon	23
PO-102	Inhibition of Cell Proliferation and Anti-apoptotic Effect by Suppression of ADMA17 Expression in Hepatocellular Carcinoma Cells	24
PO-103	ERTC Involved in HCC Growth and Metastasis Through p53 Signaling Pathway	24



Poster Exhibition Cirrhosis / Liver Fibrosis Maria Regina Cruz-Tuble PE-002 A Case of Spontaneous Bacterial Empyema in Liver Cirrhosis with Recovery after the Closed Thoracostomy and Antibiotics Treatment 127 Jeong Hwan Cho, Chang Su Kim, Jin Woo Koh, Hyun Gwang Jung, Jae Choon Pang, Guk Sang Han, Chae Ryeong Jang Dipendra Raj Pandeya, Bibek Bhatta, Yogesh Bhatta PE-004 Protective Effect of Clusterin on Hepatic Fibrosis 128 Hye-Young Seo, Yun-A Jung, Eun-Ju Lee, Keun-Gyu Park, In- Kyu Lee, Mi-Kyung Kim, Byoung Kuk Jang PE-005 Comparison of the Accuracy between Liver and Spleen Elastography Using Acoustic Radiation Force Impulse and Other Noninvasive Tests in Predicting the Presence of Esophageal Varices Yang-Hyon Baek, Sang-Young Han, Sung-Wook Lee, Jin-Sook Jeong, Hee-Jin Kwon PE-006 Head-to-head Comparisons between Collagen Proportionate Area and Acoustic Radiation Force Impulse Elastography in Liver Fibrosis Evaluation Sheng-Hung Chen, Cheng-Yuan Peng, Hsueh-Chou Lai, Jung-Ta Kao, Po-Heng Chuang, Wen-Pang Su, I-Ping Chiang Yoo Li Lim, Soon Koo Baik, Moon Young Kim, Won Ki Hong, Sang Ok Kwon Ha Young Na, Jeong Han Kim, Soon Young Ko, Won Hyeok Choe, So Young Kwon Ji Wan Kim, Jeong Han Kim, Soon Yong Ko, Won Hyeok Choe, So Young Kwon Jin Sil Pyo, Tae Hee Lee, Min Ji Park, A Reum Cho, Joo Ah Lee, Sun Hee Oh, Gi Hyun Ryu, Hoon Seop Koo, Kyoung Ho Song, Sun Moon Kim, Kyu Chan Huh, Young Woo Choi, Young Gi Dae Kim, Heon Young Lee, Byung Seok Lee, Eaum Seok Lee, Jae Kyu Sung, Hee Seok Moon, Sun Hyung Kang, Gee Young Yun, Woo Sub Kim, Seok Hyun Kim Su Hyun Lee, Se Young Jang, Sung Kyung Jang, Yu Rim Lee, Soo Young Park, Won Young Tak, Young Oh Kweon Ji-Eun Oh, Soon Koo Baik, Young Woo Eom PE-014 Two Cases with Regression of Esophageal Varices After Interferon-alpha Plus Ribavirin Therapy in Patients with Hepatitis C Virus-Related Liver Cirrhosis Soon Jae Lee, Yoo-Kyung Cho, Byung-Cheol Song Apurva Shah, Vaibhav Somani, Deepak Amarapurkar Young Don Kim, Dae Hee Choi, Ki Tae Suk, Moon Young Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim S. Borovskiy, T. Tuganbekov, N. Malayew, I. Ten, D. Tyo B. Abdrahmanov. D. Tvo D. Aribzhanov, K. Umarov Meegun Hong, Ki Tae Suk, Seungwoo Kim, Myong Jo Kim

Acute I	Liver Disease / Liver Failure	
PE-021	Clinical, Virological Features and Outcome of Acute Hepatitis B in Korean Adults from 2005 to 2014: A Single-center Experience	135
PE-022	Liver Stiffness Measurement (FibroScan®) Determines the Risk of Recurrence after Radiofrequency for Early Staged Hepatocellular Carcinon	na 126
	Soo Young Park, Se Young Jang, Won Young Tak, Young Oh Kweon, Na Ri You, Sun Kyung Jang, Yu Rim Lee, Su Hyun Lee, Keun Hur, Im Won, Hyun Young Woo, Jeong Heo, Jung Gii	
PE-023	A Case of Multiple Pyogenic Liver Abscesses Caused by Microperforation of an Idiopathic Cecal Ulcer	136
PE-024	Levocetirizine-induced Liver Injury	136
PE-025	Fatal Allopurinol Hepatotoxicity in Patient with Alcoholic Liver Cirrhosis	137
PE-026	Acute Ischemic Hepatitis Caused by Spinal Anesthesia-induced Hypotension ····· Jeong III Suh	137
PE-027	The Usefulness of Liver Fibrosis Index by Real Time Elastography in the Patients with Acute Hepatitis	137
PE-028	LXRα Agonist and Fenofibrate Combination Treatment Decreased Hepatic Inflammation in Non-alcoholic Fatty Liver Model	138
PE-029	Chronic Pancreatitis Associated with Liver Infarction and Pancreas Pseudoaneurysm: A Case Report	138
PE-030	Atypical Onset of Liver Injury Case Occurred by Bicalutamide ————————————————————————————————————	138
PE-031	Effects of Self-withdrawal of Antiviral Agents for Hepatitis B, Analyzing Acute on Chronic Liver Failure Patients Referred for Liver Transplanta	tion
	Soonkyu Lee, Jong Young Choi, Seung Kew Yoon, Si Hyun Bae, Hyun Yang, Hae Lim Lee, Dong Goo Kim, Young Kyoung You, Ji Won Han, AngeloB Lozada	139
PE-032	A Case of Acute Hepatitis A with Prolonged Cholestasis and Acute Pancreatitis	139
PE-033	Liver Fetal Cell Therapy as a Promising Approach for Patients with End-Stage Liver Disease on the Waiting List	139
PE-034	Significant Factors for Prediction of 90-day Mortality in Korean Patients Who Were Admitted with Acute Decompensation of Chronic Liver Disc	2ase
	Eileen L. Yoon, Eunhee Choi, Tae Yeob Kim, Do Seon Song, Hee Yeon Kim, Young Kul Jung, Dong Hyun Sinn, Chang Wook Kim, Dong Joon Kim	
PE-035	Acute Hepatitis A, B, C, and D in Mongolia	
PE-036	Association of Liver Enzymes with Type 2 Diabetes Mellitus: Possibility of Pathological Marker	140
PE-037	Association between Biliary Complication and Hepatic Hilum Approaches in Liver Resections	141
PE-038	Dyslipidemia in Liver Diseases: An Association for Better Management in Diabetic Patients	141
Alcoho	lic / Metabolic / Genetic / Immunologic Liver Disease	
PE-039	Diagnostic Value of Serum Gamma Glutamyl Transferase to Alkaline Phosphatase (GGT to ALP) Ratio in Patients with Alcoholic Liver Disease	
	Prabin Gyawali, Rajshree Bhujel, Siddha BahadurRana Magar, Raj Kumar Shrestha, Ram Bahadur Gurung	141
PE-040	Comparison of Deritis Ratio with Pre-existing Scoring System to Assess Severity among Patients with Alcoholic Liver Disease	142



PE-041	Bone Density in Adult Males with Non Alcoholic Fatty Liver Disease	142
PE-042	Nationwide, Population-based Epidemiology and Disease Burden of Autoimmune Hepatitis in South Korea	142
PE-043	Clinical Significance of Fatty Liver Disease Induced by Tamoxifen and Toremifene in Breast Cancer Patients	
PE-044	Systemic Review: Steroid, Pentoxifylline and Combined Therapy for Severe Alcoholic Hepatitis	
PE-045	Serum Cytokine Levels and Severity of Alcoholic Liver Disease Chan Ran You, Sang Wook Choi, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang	····· 143
PE-046	The Relationship between Serum Osteocalcin and Non Alcoholic Fatty Liver Disease	144
PE-047	Prevalence of and Factors Associated with Nonalcoholic Fatty Liver Disease in a Nonobese Korean Population	144
PE-048	The Role of GGT as a Predictor of Alcoholic Liver Disease	····· 144
PE-049	Relation of Risk Factors Between Metabolic Syndrome and Nonalcoholic Fatty Liver Disease in Young Adults	···· 145
PE-050	Effect of Thioctic Acid in NAFLD Patients with Diabetes Gi Hyun Kim, Jung Wha Chung, Eun Sun Jang, Sook-Hyang Jeong, Jin Wook Kim	····· 145
PE-051	The Prevalence of Osteoporosis in Alcoholic Cirrhotic Patients: A Priliminary Data of Multicenter Study in Gangwon Province, South Korea Tae S. Kim, Daehee Choi, Moon Y. Kim, Soon K. Baik, Ki-Tae Suk, Dong J. Kim, Young D. Kim, Gab J. Cheon	ı ··· 145
PE-052	Impact of Hypothyroidism on Development Non-alcoholic Fatty Liver Disease; 4-year Retrospective Cohort Study	···· 146
PE-053	Alcoholic Fatty Liver Disease and the Metabolic Syndrome	···· 146
Cell Bio	ology / Molecular Biology	
PE-054	Direct Conversion of Mouse Fibroblasts into Functional Integration-free Hepatocyte-like Cells	···· 146
PE-055	Direct Conversion of Fibroblasts into Bipotent Hepatic Stem Cells by Defined Factors	147
PE-056	Spectrum of Proteins Expression in the Liver Tissue and Cell Isolates in Chronic Liver Injury Model	147
PE-057	Palmitic Acid Induced Apoptosis via Inhibition of Autophagy in Hepatocytes	147
PE-058	Fermented Soymilk Prevent Free Fatty Acid-Induced Lipogenesis and Production of Reactive Oxygen Species in Hepatocellular Steatosis I	√lodel
	Sang Bong Ahn, Byoung Kwan Son, Wen Hao Wu, Jong Hun Lee, Ji Hyun Kim, Seong Yong Kim, Jin Hyun Jun	148
PE-059	Dickkopf-1 Enhances Tumor Angiogenesis and Endothelial Mesenchymal Transition	···· 148
PE-060	Hepatic Inflammatory Mediator Sphingosine-1-phosphate is Fibrogenic in Hepatic Stellate Cell Via Hippo-YAP Signaling Pathway	···· 148
PE-061	Isolation of Human Hepatocytes by A Two-Step Collagenase Perfusion Procedure from Cirrhotic Liver	····· 149

PE-062 The Combined Effect of Stem Cell Factor and Granulocyte Macrophage Colony-stimulating Factor Administration after 90% Partial Hepatectomy Dasom Choi, Yunsung Seo, Seung Duk Lee Hepatitis B, Anti-viral Therapy Jeong Han Kim, Soon Young Ko, Won Hyeok Choe, So Young Kwon Jong Seok Joo, Ju Seok Kim, Hae Jin Shin, Ki Dae Kim, Eaum Seok Lee, Seok Hyun Kim, Heon Young Lee, Byung Seok Lee Seung Suk Baek, Eileen L. Yoon, Wook Hyun Yeo, Hyung Gy Bae, Yu Ri Hwang, So Young Ahn, Ji Young Park, Jung Min Choi, Tae Joo Jeon, Won Chang Shin, Won-Choong Choi PE-066 HBV-DNA and Clinical Characteristics of Patients Who Developed HCC while Receiving Tenofovir Disoproxil Furnarate (TDF) Following 8 Years of W. Ray Kim, Rohit Loomba, Thomas Berg, Raul Aguilar Schall, Leland J. Yee, Phillip Dinh, John F. Flaherty, Eduardo B. Martins, Terry Therneau, Ira Jacobson, Scott Fung, Selim Gurel, Maria Buti. Patrick Marcellin Patrick Marcellin, Edward J. Gane, Robert Flisiak, Huy N.Trinh, Joerg Petersen, Selim Gurel, Kelly D. Kaita, Iskren A. Kotzev, Naoky Tsai, John F. Flaherty, Raul E. Aquilar Schall, Kathryn M. Kitrinos, Mani Subramanian, John G. McHutchison, Jacob George, Harry L. Janssen, Jin Youn, Maria Buti W. Ray Kim, Rohit Loomba, Thomas Berg, Raul Aguilar Schall, Leland J. Yee, Phillip Dinh, John F. Flaherty, Eduardo B. Martins, Terry Therneau, Ira Jacobson, Scott Fung, Selim Gurel, Maria Buti, Patrick Marcellin PE-069 Efficacy of Switching from Adefovir to Tenofovir in Chronic Hepatitis B Patients with a Suboptimal Response to Adefovir-based Combination Rescue Hye Won Lee, Jun Yong Park, Kyu Sik Jung, Wonseok Kang, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Kwang-Hyub Han, Sang Hoon Ahn PE-070 The Result of Complete Virological Response of Tenofovir Dipivoxil Fumarate Monotherapy for Nucleos(t)ide Analogue Naïve and Nucleos(t)ide Sun Hee Oh, Tae Hee Lee, Min Ji Park, A Reum Cho, Joo Ah Lee, Ki-Hyun Ryu, Hoon Sup Koo, Kyung Ho Song, Sun Moon Kim, Kyu Chan Huh, Young Woo Choi, Young Woo Kang Kyu Sik Jung, Hye Won Lee, Goo Hye Jin, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Sang Hoon Ahn PE-072 Adefovir-associated Fanconi Syndrome Presenting as Repeated Multiple Pathologic Bone Fracture due to Hypophosphatemic Osteomalacia · 153 So Jung Yeo, Baek Gyu Jun, Sae Hwan Lee, Hong Soo Kim, Sang Gyune Kim, Young Seok Kim, Boo Sung Kim, Soung Won Jeong, Jae Young Jang, Young Don Kim, Gab Jin Cheon Eun-Hyung Yoo, Tae Hee Lee, Young Woo Kang, Hyun-Jung Cho PE-074 Delayed Serologic Response in Multi-drug Resistant CHB Patients with Tenofovir and Entecavir Combination Therapy in Real Practice 154 Sung Won Lee, Jung Hyun Kwon, Jain Lee, Nam Ik Han, Young Woon Kim, Soon Woo Nam, Kyu Won Chung, Jeong Won Jang Mi Young Kim, Soo Hyung Ryu, Soo Yeon Jo, Sung Won Park, Won Jae Yoon, Jeong Seop Moon Hye Young Jwa, Yoo-Kyung Cho, Eun Kwang Choi, Heung Up Kim, Hyun Joo Song, Soo-Young Na, Sun-Jin Boo, Seung Uk Jeong, Bong Soo Kim, Byoung-Wook Lee, Byung-Cheol Song Sungsoo Byun, Mu-yeol Lee, Jung Woo Shin, Bo Ryung Park, Min-Ho Kim, Chang Jae Kim, Byung Uk Lee, Jae Ho Park, Byung Gyu Kim, Seok Won Jung, In Du Jeong, Sung-Jo Bang, Neung Hwa Park Ali Pekcan Demiroz, Cigdem Ataman Hatipoglu, Cemal Bulut, Nesrin Ata, Esra Kaya Kilic, Sami Kinikli, Ali P. Demiroz PE-079 Safety and Efficacy of Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B between Decompensated and Compensated Cirrhosis Myeong Jun Song, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Byung Seok Lee, Tae Hee Lee, Suk Bae Kim, Hee Bok Chae, Il soon Jeong, Soon Young Ko



Hepati	tis B, Others
PE-080	Prevalence and Risk Factors of Hepatitis B Surface Antigen Carriage in Central Nepal: A Hospital based Study
PE-081	Role of IL28B Polymorphisms in the Treatment Response of Entecavir in Treatment Naïve Chronic Hepatitis B Patients
PE-082	A Case of Hepatic Decompensation in Pregnant Woman with Chronic Hepatitis B
PE-083	Clonal Analysis of Full-length Genome and Characterization of Surface Antigenicity of Entecavir-resistant Hepatitis B Virus Isolated from Chronic Hepatitis B Patients
PE-084	The Substitution at rt269 in Hepatitis B Virus Polymerase Is Associated with the Multi-drug Resistance as a Compensatory Mutation
PE-085	The Impact of the Hepatitis B Virus Polymerase rtA181T Mutation on Replication and Drug Resistance Is Potentially Affected by Overlapping Changes in Surface Gene
	So Ree Park, Sung Hyun Ahn, Yong Kwang Park, Eun-Sook Park, Doo Hyun Kim, Ah Ram Lee, Hong Seok Kang, Kyun-Hwan Kim
PE-086	Processing of c-FLIP is Involved in TNF-a-mediated Suppression of HBV
PE-087	Risk Factors for HBV Reactivation in Patients Underwent Hematopoietic Stem Cell Transplantation in HBV Endemic Area
PE-088	Profile of Patients Diagnosed with Fatty Liver Disease at Seamen's Hospital
PE-089	Men Seropositive for Hepatitis B Surface Antigen Are at Risk of Lower Bone Mineral Density: the 2008-2010 Korea National Health and Nutrition Examination Surveys
PE-090	Viral Hepatitis: A Bug of Increasing Concern
Hepatitis C	
PE-091	HCV
PE-092	The Significance of Change of Mean Corpuscular Volume (MCV) During Treatment of Chronic Hepatitis C
PE-093	Development of Novel Infectious Clones of Genotype 1 Hepatitis C Virus
PE-094	Safety and Efficacy Outcomes of All-oral Daclatasvir-Containing Regimens in Patients with or without Cirrhosis in Phase 2 and 3 Studies · · · 161 D.M. Jensen, I.M. Jacobson, H. Kumada, J. Toyota, M. Sulkowski, M. Manns, J.H. Kao, J. Heo, P.D. Yin, P. Mendez, E.A. Hughes, S. Noviello
PE-095	
	100% SVR12 in Japanese Patients with Chronic GT1 HCV Infection Receiving Ledipasvir/Sofosbuvir for 12 Weeks: A Multicenter Phase 3 Study
	100% SVR12 in Japanese Patients with Chronic GT1 HCV Infection Receiving Ledipasvir/Sofosbuvir for 12 Weeks: A Multicenter Phase 3 Study 162 Masashi Mizokami, Tetsuo Takehara, Osamu Yokosuka, Naoya Sakamoto, Masaaki Korenaga, Hitoshi Mochizuki, Kunio Nakane, Hirayuki Enomoto, Mikio Yanase, Hidenori Toyoda, Fusaa (keda, Takuya Genda, Takeji Umemura, Hiroshi Yatsuhashi, Tatsuya Ide, Nobuo Toda, Kazushige Nirei, Yoshiyuki Ueno, Yoichi Nishigaki, Juan Betular, Bing Gao, Akinobu Ishizaki, Masa Omote, SunJin Hwang, Phillip S. Pang, Steven J. Knox, William T. Symonds, John G. McHutchison, Namiki Izumi, Masao Omata
PE-096	162 Masashi Mizokami, Tetsuo Takehara, Osamu Yokosuka, Naoya Sakamoto, Masaaki Korenaga, Hitoshi Mochizuki, Kunio Nakane, Hirayuki Enomoto, Mikio Yanase, Hidenori Toyoda, Fusaa (keda, Takuya Genda, Takeji Umemura, Hiroshi Yatsuhashi, Tatsuya Ide, Nobuo Toda, Kazushige Nirei, Yoshiyuki Ueno, Yoichi Nishigaki, Juan Betular, Bing Gao, Akinobu Ishizaki, Masa
PE-096 PE-097	Masashi Mizokami, Tetsuo Takehara, Osamu Yokosuka, Naoya Sakamoto, Masaaki Korenaga, Hitoshi Mochizuki, Kunio Nakane, Hirayuki Enomoto, Mikio Yanase, Hidenori Toyoda, Fusaa Ikeda, Takuya Genda, Takeji Umemura, Hiroshi Yatsuhashi, Tatsuya Ide, Nobuo Toda, Kazushige Nirei, Yoshiyuki Ueno, Yoichi Nishigaki, Juan Betular, Bing Gao, Akinobu Ishizaki, Masa Omote, SunJin Hwang, Phillip S. Pang, Steven J. Knox, William T. Symonds, John G. McHutchison, Namiki Izumi, Masao Omata 97% SVR in Japanese Patients with Chronic GT2 HCV Infection Receiving Sofosbuvir + Ribavirin for 12 Weeks: A Phase 3 Study

PE-099	Depression in Chronic Hepatitis C: Prevalence and Incidence during Antiviral Therapy	164
PE-100	Sofosbuvir Population Pharmacokinetics in Korean Subjects with Chronic Genotype 2 HCV Infection	164
PE-101	Population Pharmacokinetic Analysis of Ledipasvir/Sofosbuvir Fixed Dose Combination Tablet in Korean Subjects with Chronic Genotype 1 H Infection	
PE-102	Clinical Features and Outcomes of Patients with Hepatitis C Virus Genotype 3 in Korea	165 <i>Lee</i>
PE-103	Regional Differences of HCV Genotype in Jeollanam-do Province	166
PE-104	Clinical Characteristics of Chronic Hepatitis C in the Elderly Patients	166
PE-105	Factors Related to Effective Treatment for Aged Patients with Chronic Hepatitis C with Pegylated Interferon and Ribavirin Combination Thera	ару
	Soon Young Ko, Tae Hee Lee, Suk Bae Kim, Hong Soo Kim, Baek Gyu Jun, An Na Kim, Ji Woong Jang, Myeong Jun Song, Jeong Rok Lee, Tae Young Jung, Byung Seok Lee, Hee Bok C	
PE-106	Hepatitis C Virus Suppresses Interferon-stimulated Production of Immunoproteasomes by the Protein Kinase R Pathway	167
PE-107	Interleukin-28B Polymorphisms and Response of Peg-IFN/ Ribavirin Treatment in Chronic Hepatitis C Patients	167
PE-108	Clinical and Economic Outcomes of Treating Immediately with Daclatasvir Plus Asunaprevir Versus Delaying Treatment for HCV Patients in Sou Korea	
	Do Young Kim, Byungyool Jun, Tae Hyun Kim, Sohee Park, Thomas Ward, Phil McEwan	
PE-109	Cyclophilin Inhibitors Restore Attenuated Expression of MHC Class I Molecule in HCV-infected Cells	168
PE-110	Significance of Insulin Resistance in Chronic Hepatitis C Patients after Peg-interferon Based Therapy	168
PE-111	Estimation of Direct Medical Cost related to the Management of Chronic Hepatitis C and Its Complications in Korea	168
PE-112	Elimination of Hepatitis C Virus (HCV) in South Korea	169
PE-113	Seroprevalence of Hepatitis C Infection and Risk Factor Assessment: A Hospital based Study **Dhruba Acharya, Bikash Bogati, Sarita Bhandari, Sashi Wenju** **Darita Barta Bart	169
Liver C	ancer, Basic	
PE-114	Chromatin Remodeler SNF5 as Therapeutic Targets in Liver Cancer	170
PE-115	In Vivo HCC-targeting Gene Therapy by Trans-splicing Ribozyme and Liver-specific Promoter Augumented by Rebuilded Adenoviral Construct a microRNA Regulation	and 170
PE-116	The Hepatitis B Virus X Protein Induces the Phenotype of Epithelial-mesenchymal Transition through Control CD44 in HCC Cell Lines	170
PE-117	The Roles of Kras Isoforms in Liver Cancer	171
PE-118	Inhibition of Discoidin Domain Receptor 2 May Enhance the Antitumor Effect of Sorafenib in a Hepatocellular Carcinoma Patient-Derived Xenogr (PDX) Model	raft 171
PE-119	Development of Hepatocellular Carcinomas in the Background of Liver Fibrosis Using a Transgenic Mouse Model	172



PE-120	Differential Tumorigenic Effects by c-Myc Mutants in Liver Cancer
PE-121	Demographic Profile and Treatment Outcomes of Filipino Patients with Hepatocellular Carcinoma in a Liver Tumor Registry
PE-122	Up-regulation of miR-128 in the Pathogenesis of Hepatocellular Carcinoma
PE-123	Inhibition of Integrin Linked Kinase Augments Sorafenib Sensitivity of Hepatocellular Carcinoma Cells by Up-regulation of Anoikis
Liver C	ancer, Clinical
PE-124	Comparison of the Clinical Features of Hepatocellular Carcinoma with Cryptogenic, Alcohol, and Viral Hepatitis Etiologies
PE-125	Short-term Outcome of Laparoscopic Radiofrequency Ablation for Hepatocelluar Carcinoma in Liver Cirrhosis: The Safety and Efficacy · · · · · 174 Byung Gon Na, Chan Woo Cho, Nuri Lee, Dong Kyu Oh, Wontae Cho, Jin yong Choi, Seung Hwan Lee, Sang Hoon Lee, Gyu Seong Choi, Jong Man Kim, Choon Hyuck Kwon, Jae-Won Joh, Jae Berm Park, Sung Joo Kim, Suk-Koo Lee
PE-126	Role of Enhancement Degree of Gd-EOB-DTPA-enhanced Magnetic Resonance Images for Prediction of Histologic Grade of Hepatocellular Carcinoma; Prospective Cohort Study
PE-127	Prediction of Clinical Outcome after Radioembolization in HCC Patients: Role of 18F-FDG PET-CT
PE-128	The Meaning of AFP, AFP-L3 and PIVKA-II for Evaluating Recurrence in Patients with Hepatocellular Carcinoma Who Underwent Liver Resection 175
	Sung Hoon Kim, Mee-Yon Cho, Moon Young Kim, Soon Koo Baik
PE-129	Evaluation of Fine Needle Aspiration Cytology of Malignant Mass Lesions of Liver
PE-130	Combination Treatment of Trans-arterial Chemoemobolization Followed by Radiotherapy with HyperThermia (CERT) in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Interim Analysis of Prospective Phase II Trial
PE-131	Combined Transarterial Chemoembolization and Radiotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: An External Validation Study of Clinical Significance
PE-132	Clinical Significance of Occult Hepatitis B Infection in Patients with Non-hepatitis B/Non-Hepatitis C-related Hepatocellular Carcinoma in a Hepatitis B Endemic Area
PE-133	The Role of 18F-fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) for Accurate Staging and Optimal Treatment Planning in Patients with Hepatocellular Carcinoma 177 Kyung Woo Park, Sang Gyune Kim, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Sae Hwan Lee, Hong Soo Kim, Boo Sung Kim, Jung Mi Park
PE-134	Glypican-3 Level Assessed by Enzyme-linked Immunosorbent Assay is Inferior to Alpha Fetoprotein For Hepatocellular Carcinoma Diagnosis
	Yejoo Jeon, Yun Suk Choi, Eun Sun Jang, Jin-Wook Kim, Sook-Hyang Jeong
PE-135	Radiation Therapy for Para-aortic Lymph Node Metastasis in Patients of Hepatocellular Carcinoma
PE-136	Risk Factors for Predicting Infectious Fever in Hepatocellular Carcinoma Patients with Fever after Transarterial Chemoembolization
PE-137	Antiviral Treatment after Curative Therapy of HBV-related HCC Improves the Outcome in Patients with High Serum HBV DNA Level
PE-138	Comparative Analysis of Laparoscopic versus Open Surgical for Malignant Liver Tumors

PE-139	Three-dimensional Conformal Radiotherapy for Portal Vein Tumor Thrombosis in Advanced Hepatocellular Carcinoma	179
PE-140	Oral Medications Improve the Compliance to Regular Surveillance for Hepatocellular Carcinoma in Chronic Hepatitis B Patients	
PE-141	Long-term Outcome after Resection of Huge Hepatocellular Carcinoma ≥10 cm: Single-institution Experience with 471 Patients ······ Shin Hwang, Young-Joo Lee, Ki-Hun Kim, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Sung-Gyu Lee	179
PE-142	Model for Predicting Treatment Response of Sorafenib in Patients with Advanced Hepatocellular Carcinoma Dong Hyeon Lee, Su Jong Yu, Yuri Cho, Jung-Ju Yoo, Minjong Lee, Young Youn Cho, Eun Ju Cho, Jeong-Hoon Lee, Yoon Jun Kim, Jung-Hwan Yoon	180
PE-143	Clinical Features and Treatment Modalities of Long-Term Survivors with Advanced Hepatocellular Carcinoma: A Single Institution Cohort Str	udy 180
	Kyung Hee Kim, Bo Hyun Kim, Chang-Min Kim, Byung Ho Nam, Joong-Won Park	
PE-144	High Dose and Compartmental Target Volume May Improve Outcome of Radiotherapy for Pelvic Bone Metastases from Hepatocellular Carcino	oma 181
	Tae Hyung Kim, Hye Jung Cha, Jun Won Kim, Jinsil Seong, Ik Jae Lee	
PE-145	Pseudocirrhosis as a Potential Mimic of Infiltrative Hepatocellular Carcinoma	181
PE-146	Development of Hepatocellular Carcinoma in Patients Outside Current Treatment Recommendation by KASL Guideline	181
PE-147	Factors Predicting Hepatocellular Carcinoma Progression and Poor Prognosis after Transarterial Chemoembolization	182
PE-148	Is Totally Laparoscopic Approach for Left Hepatectomy the Reliable Procedure Even in Cases with Severe Peri-Hepatic Adhesion?	182
PE-149	Percutaneous Ethanol Injection Therapy is Comparable to Radiofrequency Ablation in Early Stage Hepatocellular Carcinoma: Long-Term Outcomed Prognostic Factors	mes 182
PE-150	Repeated Stereotactic Body Radiotherapy for Recurrent Hepatocellular Carcinoma	183
PE-151	Immunohistochemical Markers for Prognosis of Hepatocellucar Carcinoma after Liver Resection and Liver Transplantation	183
PE-152	Treatment Outcome and Prognosis of Patients with Hepatocellular Carcinoma with Inferior Vena Cava and/or Cardiac Invasion	184
PE-153	Surgical Outcomes of Laparoscopic Right Hepatectomy Using the Combined Approach Compared with The Conventional Approach Sung-Hwa Kang, Ki-Hun Kim	184
PE-154	Transarterial Chemoembolisation in Treatment of Liver Tumors in Accordance with Features of Their Angioarchitecture	184
PE-155	TACE in the Treatment of Hepatocellular Carcinoma in Kazakhstan (Southern Part)	185
PE-156	Effectiveness of Surveillance on Early Diagnosis of Hepatocellular Carcinoma	185
PE-157	Prognostic Factors of Intrahepatic Cholangiocarcinoma Revisited	186
PE-158	Living Donor Liver Transplantation after Combined Transarterial Chemoembolization and Radiotherapy for Hepatocellular Carcinoma with Ma	
	Yuri Jeong, Sang Min Yoon, Min-Ho Shin, Gi-Won Song, Ki-Hun Kim, Chul-Soo Ahn, Deok-Bog Moon, Shin Hwang, Jong Hoon Kim, Sung-Gyu Lee	100



Liver Tr	ransplantation
PE-159	Technical Knacks to Enhance Luminal Patency of Interposed Synthetic Graft in Living Donor Liver Transplantation Using Modified Right Liver Graft
	Seok-Hwan Kim, Shin Hwang, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Chul-Soo Ahn, Deok-Bog Moon, Ki-Hun Kim, Gil-Chun Park, Bo-Hyun Jung, Sung-Hwa Kwang, Young-Ir. Yoon, Min-Ho Shin, Wan-Jun Kim, Kang Woo-Hyoung, Sung-Gyu Lee
PE-160	Comparison of Technical Handling and Luminal Patency between Interposed PTFE Grafts with Interrupted Rings versus Continuous Spiral Rings in Living Donor Liver Transplantation Using Modified Right Lobe Graft Seok-Hwan Kim, Shin Hwang, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Chul-Soo Ahn, Deok-Bog Moon, Ki-Hun Kim, Gil-Chun Park, Bo-Hyun Jung, Sung-Hwa Kwang, Young-In
PE-161	Yoon, Min-Ho Shin, Wan-Jun Kim, Woo-Hyoung Kang, Sung-Gyu Lee Hepatitis B Virus-related Mixed Hepatocellular-Cholangiocarcinoma in Patients Undergoing Liver Transplantation
PE-162	The Start of Liver Transplantation at the Public Hospital in Korea
PE-163	A Case of Early Organizing Portal Vein Thrombosis Followed by Arterio-Portal Shunt without Hepatic Dysfunction after Liver Transplantation
	Tae-Seok Kim, Koo Jeong Kang, Keun Soo Anh, Yong Hoon Kim, Hyoung Tae Kim
PE-164	Effectiveness of Continuous Wound Infusion of Ropivacaine for Postoperative Pain Management after Donor Hepatectomy in Living Donor Liver Transplantation
PE-165	Renal Function Difference between Anti-Hepatitis B Immunoglobulin(HBIG) Monotherapy and HBIG Combined with Entecavir
PE-166	Biliary Complication after Living Donor Liver Transplantation According to Biliary Reconstruction Methods
PE-167	Post-transplant Lymphoprolieferative Diseases in Pediatric Liver Recipients
PE-168	Donor Safety and Recipient Liver Function Following Right- lobe Liver Transplantation from Donor with Gilbert Syndrome
PE-169	Single-center Experience of ABO Incompatible Living Donor Liver Transplantation with New Simplified Intravenous Immunoglobulin Protocol: A Propensity Score Matching Analysis
PE-170	Transplant Program Development in Kazakhstan: Experience of 11 Years
PE-171	Experience from the First Liver Transplant Program in Kazakhstan
PE-172	Tuberculosis after Living Donor Liver Transplantation
PE-173	Rapid Progression of Alcoholic Steato-hepatitis after Liver Transplantation : A Case Report Seung Hwan Song, Juhan Lee, Jae Geun Lee, Myoung Soo Kim, Dai Hoon Han, Gi Hong Choi, Jin Sub Choi, Soon Il Kim, Dong Jin Joo
Surgery	
	The Role of International Collaborative Program in Development of Adult-to-adult Living-donor Liver Transplantation Program in National Scientific Medical Research Center
	Doskali M, Lee KW, Saparbay J, Choi YR, Suh SW, Kuttymuratov G, Rysmakhanov M, Kushenova S, Taganova A, Kulmaganbetov A, Smagulov A, Seidakhmetov A, Baigenzhin A, Doskaliyet Zh
PE-175	Successful Treatment of Hydatid Cysts Caused by Echinococcus Multilocularis Using High-intensity Focused Ultrasound: 3-Year Follow up Management 194 Kulmaganbetov A, Doskali M, Imankulov S, Baigenzhin A, Doskaliyev Zh

PE-176	Single Center Experience of Management of Large Hepatic Hemangiomas · · · · · Taganova A, Doskali M, Rysmakhanov M, Tashev I, Doskaliyev Zh, Baigenzhin A	194
PE-177	Management of Hepatic Multivesicular and Complicated Hydatid Cysts: Surgical Options and Postoperative Care	194
PE-178	Regional Development of Living Donor Kidney Transplantation in Kazakhstan. Results and Prospects	194
PE-179	Sofosbuvir + Peg-Interferon + Ribavarin Therapy Result for A Patient with Hepatitis C Virus Related Liver Cirrhosis and Hypersplenism ··· <i>Ts. Enkh-Amgalan, N. Batsaikhan, A. Bold, E. Gerelmaa, B. Dulguun, G. Sarantuya</i>	195
PE-180	A Case of Bile Duct Adenoma Developed in Hepatic Hilar Portion Mimicking Klatskin's Tumor	195
PE-181	Combined Targeting of mTORC1 and mTORC2 Synergistically Inhibits Proliferation of Hepatocellular Carcinoma Cells: Effects of Everolin Ku0063794	nus and ···· 196
PE-182	Lipopolysaccharide Preconditioning of Adipose-derived Stem Cells Improves Liver-regenerating Activity of The Secretome	196
PE-183	The Liver Graft Adaptation to the Early Hepatic Artery Occlusion after Living Donor Liver Transplantation Case Report	197
PE-184	Results of Splenic Artery Embolization Following Adult-to- adult Living Donor Liver Transplantation	197
PE-185	Lymph Node Ratio vs. Total Number of Lymph Node Metastasis for Prediction of Oncologic Outcome in Pancreatic Head Cancer **Jar Uk Chong, Chang Moo Kang**	197
PE-186	Defining Practical N-staging System to Predict Oncologic Outcome in Resected Left Sided Pancreatic Cancer	198
PE-187	The Significance of Lymph Node in Pancreatic Neuroendocrine Tumors: Is Dissection Absolutely Necessary?	199
PE-188	X-Ray Endovascular Intervention in Portal Hypertension	199
PE-189	Real-Life Effectiveness of Different Antiviral Therapy Regimens in Treatment of HDV-Infection	200
PE-190	The Results of Transarterial Chemoembolization for Malignant Liver Tumors	200
PE-191	Surgical Approach Did Not Impact on Oncology Outcome in Middle Bile Duct Cancer; Bile Duct Segmental Resection vs. Pancreaticoduoder	
	Jiae Park, Chang Moo Kang	
PE-192	Feasibility of Enhanced Recovery after Surgery Pathway in Pancreaticoduodenectomy for Non-surgical Complication Patients	201
PE-193	Laparoscopic Enucleation of Pancreatic Benign Neoplasm; Single Center Experience	···· 201
PE-194	Clinical Feautures of Curatively Resected Neuroendocrine Carcinoma of the Gallbladder	202
PE-195	Aggressive Radical Resection for Type IIIb Compared to Type IIIa Hilar Cholangiocarcinoma	202
PE-196	Hepatic Allograft Salvage in LDLT after Early HAT by Combined Surgical and Angiographic Techniques	
PE-197	Experience of Related Liver Transplantation	202
PE-198	Reconstructive Surgery for Bile Duct Strictures	203



PE-199	Jaime Yap Haw Jr, Arsenio Lim Co	203
Others		
PE-200	Enhanced Direct Conversion of Fibroblasts into Hepatocyte- like Cells via Accelerated Reprogramming Kinetics	··· 203
PE-201	Primary Paraganglioma of Liver: A Rare Tumor at an Unusual Location ···· Jeong Eun Song, Sang Ah Baek, Byeong Suk Kim, Chang Hyeong Lee	204
PE-202	Obscure Overt Gastrointestinal Bleeding from Jejunal Varices: a Case Report	··· 204
PE-203	A Case of Alcoholic Liver Cirrhosis First Presenting with Dyspnea due to Portopulmonary Hypertension	··· 205
PE-204	A Case of Primary Gastrointestinal Stromal Tumor of the Liver	205
PE-205	Complication of Amebic Liver Abscess: Biliary Fistula	··· 205
PE-206	The Necessity of Computed Tomography to Hepatic Lesions Detected on Private Clinic Sonography	206
PE-207	Predictors of Early Regeneration in Remnant Liver Volume after Hepatectomy Jae Do Yang, Woo Sung Moon, Baik Hwan Cho, Hee Chul Yu	206
PE-208	Association of Erectile Dysfunction with Depression in Patients with Chronic Viral Hepatitis	206
PE-209	A Case of Acute Q Fever and Hepatitis Followed by High Long-term Titers Indicative of an Undetermined Stage	207
PE-210	Laparoscopic Excision versus Unroofing for a Giant Hepatic Cyst	207
PE-211	Biomarker stratified, Prospective Clinical Trial to Assess the Efficacy of Hepatic Arterial Infusion of Cisplatin and 5-fluorouracil in HCC Jung-Hee Kwon, Moo-Sang Kim, Jin Young Park, Yun Suk Yu, Si Hyun Bae, Hee Jung Wang	··· 207
SYMPO	SIUM 1 Consensus Meeting on the Noninvasive Diagnosis of Cirrhosis	
Noninva Laurent C	asive Tools for the Diagnosis of Cirrhosis: Is TE Not Enough by Itself?	··· 211
Optimal Do Young	Cutoff Value of Transient Elastography for the Diagnosis of Cirrhosis ···································	··· 212
	asive Evaluation of Liver Fibrosis in China	··· 213
Special	Lecture 1	
Acute o	n Chronic Liver Failure ········oreau	··· 217
SYMPO	DSIUM 2 Liver-Gut Axis	
Microbi	ome and the Liver - Clinical Implications ····································	221
Cutting	edge Methods of Human Microbiota Research Using Korean Twins ····································	222

Can We Modulate Microbiome? 223 Yoon-Keun Kim
Liver-Gut Axis: Fibrosis and HCC
VIRAL HEPATITIS FORUM I HCV: From Discovery to Eradication
HCV: Virus Life Cycle and Targets of DAA 229 Seungtaek Kim
History of Drugs: From Interferon to DAA
Treatment Options: West vs. East
Hepatitis C virus Coopts Host Ankyrin Repeat Domain 1 for Its Own Propagation ————————————————————————————————————
VIRAL HEPATITIS FORUM II HBV: From Discovery to Eradication
The Virus and Pathogenesis 237 Yasuhito Tanaka
Treatment: Two Decades of Progress 238 Jia-Homg Kao
Revisit Quantitative HBsAg and cccDNA 239 Man-Fung Yuen
New Trials Toward a Cure 240 Sang Hoon Ahn
ASIA-PACIFIC JOINT SYMPOSIUM I HBV: Immuno-and Bio-therapeutic Approach to Cure Chronic Hepatitis B Virus Infection
Immunopathogenesis of HBV Infection and Principle of Immunotherapy for HBV Infection
Clinical Experience of HBV DNA Vaccine in Korean Patients with Chronic HBV Infection — 244 Seung Kew Yoon
Optimized Immunotherapy to Cure Chronic HBV Infection by Using a Convenient Immuno-competent Mouse Model
ASIA-PACIFIC JOINT SYMPOSIUM II Management of Chronic Hepatitis C: Clinical Issues and Future Perspective
Hepatitis C: National-wide Screening of HCV
Hepatitis C: Interferon-based Regimens, Still Useful or Useless? 256 Young Seok Kim
Future Use of DAAs in Asia-Pacific Region 257 Ming-Lung Yu
ASIA-PACIFIC JOINT SYMPOSIUM III Management of Chronic Hepatitis B: Clinical Issues and Future Perspective
Management of Chronic Hepatitis B: Nation-wide Cohort Studies
Management of HBV Antiviral Resistance 262 Young-Suk Lim



HBV Treatment Initiation and Cessation Criteria	264
Beyond the Antiviral Therapy to Reduce the Risk of Liver Cancers in Chronic Hepatitis B	265
CLINICAL HEPATOLOGY UPDATE ASH and NASH	
Mechanism-based New Target for Therapy in ASH	269
To Drink or Not To Drink? That is the Question ····· Seung Ha Park	270
Management of Alcohol Dependence in Clinic ····· Suk Bae Kim	271
Drug Therapy for NAFLD: What is New? <i>Yun Soo Kim</i>	280
SYMPOSIUM 3 Debates in the Treatment of Portal Hypertension	
Antibiotic Prophylaxis: Which Drug, For Whom, For How Long?	287
Coagulopathy: Is It a Complication or a Treatment Target?	292
Minimal Hepatic Encephalopathy: Should Be Treated or Not? B. C. Sharma	293
Radiological Intervention: When Should It Be Considered in Patients with Complications of Portal Hypertension?	294
SPECIAL LECTURES 2 Emerging Trends in Treatments of Chronic Liver Disease	
SPECIAL LECTURES 2 Emerging Trends in Treatments of Chronic Liver Disease New Paradigms for Hepatitis C W. Ray Kim	297
New Paradigms for Hepatitis C	
New Paradigms for Hepatitis C W. Ray Kim The Evolution of HCC Treatment	299
New Paradigms for Hepatitis C W. Ray Kim The Evolution of HCC Treatment Masatoshi Kudo Fifty Years of Japanese Hepatology: Past, Present and Future	299
New Paradigms for Hepatitis C W. Ray Kim The Evolution of HCC Treatment Masatoshi Kudo Fifty Years of Japanese Hepatology: Past, Present and Future Kazuhiko Koike	299
New Paradigms for Hepatitis C W. Ray Kim The Evolution of HCC Treatment Masatoshi Kudo Fifty Years of Japanese Hepatology: Past, Present and Future Kazuhiko Koike STATE-OF-THE-ART LECTURE Non-invasive Tools for the Diagnosis and Management of Cirrhosis	299
New Paradigms for Hepatitis C W. Ray Kim The Evolution of HCC Treatment Masatoshi Kudo Fifty Years of Japanese Hepatology: Past, Present and Future Kazuhiko Koike STATE-OF-THE-ART LECTURE Non-invasive Tools for the Diagnosis and Management of Cirrhosis Laurent Castera	
New Paradigms for Hepatitis C W. Ray Kim The Evolution of HCC Treatment Masatoshi Kudo Fifty Years of Japanese Hepatology: Past, Present and Future Kazuhiko Koike STATE-OF-THE-ART LECTURE Non-invasive Tools for the Diagnosis and Management of Cirrhosis Laurent Castera KASL & KSSCR JOINT SYMPOSIUM Liver Regeneration: Where We Are Basic Techniques: Hepatocytes and Matrix (Bioartificial Liver)	
New Paradigms for Hepatitis C W. Ray Kim The Evolution of HCC Treatment Masatoshi Kudo Fifty Years of Japanese Hepatology: Past, Present and Future Kazuhiko Koike STATE-OF-THE-ART LECTURE Non-invasive Tools for the Diagnosis and Management of Cirrhosis Laurent Castera KASL & KSSCR JOINT SYMPOSIUM Liver Regeneration: Where We Are Basic Techniques: Hepatocytes and Matrix (Bioartificial Liver) Suk-Koo Lee Feasibility of Placenta-derived Stem Cells on Hepatic Failure Models	

KLTS COORDINATOR PROGRAM The Role of Coordinator in Liver Transplant Field
Registration and Management of the Patients on Waiting List
Pre-transplant Education and Counseling for the Liver Recipients
Post-transplant Education and Counseling for the Liver Recipients
KLTS SYMPOSIUM HCC Recurrence after Liver Transplantation
Selection and Down-staging of Advanced HCC for Liver Transplantation
Preventive Treatment for HCC Recurrence after Liver Transplantation: Role of mTOR Inhibitor and Adjuvant Treatment
How to Diagnose and Manage HCC Recurrence after Liver Transplantation
KHBPS & KLTS JOINT SYMPOSIUM Care for Long-term Survivor after Liver Transplantation
Post-liver Transplantation Metabolic Syndrome 337 Jaeseok Yang
Surveillance of Recurrence and De Novo Solid Tumors - De Novo Malignancies after Liver Transplantation: Incidence, Diagnosis and Treatment 338 Shin Hwang
Histopathology of Allograft Dysfunction in Late Period of Liver Transplantation
Allograft Dysfuction: Mechanism and Prevention 342 Hiroto Egawa
KHBPS & JSHBPS JOINT SYMPOSIUM 1 Recent Change in the Concept and Treatment in Cholangiocarcinoma
Changing Patterns of Incidence and Treatment Strategy for Cholangiocarcinoma
Relationship between Recurrence Pattern of Intrahepatic Cholangiocarcinoma after Hepatic Resection and Hepatitis Virus (Multi-institutional Research) -ls Lymph Node Dissection Necessary? 346 Masaki Kaibori, Hiroya lida, Hiroaki Nagano, Michihiro Hayashi, Takuya Nakai, Shigekazu Takemura, Hiroshi Wada, Fumitoshi Hirokawa, Yasuyuki Nakata, Shoji Kubo
Update in Non-surgical Treatment in Cholangiocarcinoma
KHBPS & JSHBPS JOINT SYMPOSIUM 2 (Video Session) Lessons Learned from the Experts: How I Do Major Hepatic Resection?
Major Hepatic Resection for Hepatobiliary Cancer with Portal Venous Involvement
Anti-Situm In-situ Hypothermic Perfusion Hepatectomy for Liver CA on HV Confluence 352 Sung-Gyu Lee
Surgical Challenge Beyond the Current Limit for Advanced Hepatocellular Carcinoma (HCC) with Extensive Portal Vein Tumor Thrombosis (PVTT) ··· 353 Yonson Ku, Motofumi Tanaka, Takumi Fukumoto
KHBPS & JSHBPS JOINT SYMPOSIUM 3 (Video Session) Lessons Learned from the Experts: How I Do Donor Hepatectomy?
Various Types of Donor Resection, Left Side



Various Types of Donor Resection - Right Side Liver Graft	- 358
Various Types of Donor Resection in Japan via Midline Incision	359
KLCSG & KHBPS JOINT SYMPOSIUM	
Optimal Selection of Surgical Candidate in Non-conventional Setting	363
Antiviral Therapy for the Prevention of HCC Recurrence after Surgical Resection	364
Surgery for HCC Patients with Portal Vein or Bile Duct Invasion	·· 367
Surgical Resection versus Transcatheter Arterial Chemoembolization Followed by Radiation Therapy for the Treatment of Hepatocellular Carcinoma Segmental/Subsegmental Portal Vein Tumor Thrombus	with 368
KLCSG & LCSGJ JOINT SYMPOSIUM	
HCC Nationwide Surveillance and Outcome in Korea	·· 371
HCC Nationwide Surveillance and Outcome in Japan	·· 372
Indication of Surgical Resection and Pre-operative Evaluation for HCC in Korea	·· 373
Indication of Surgical Resection and Pre-operative Evaluation for HCC in Japan	·· 376
Advance in Transarterial Treatment: Conventional TACE Shiro Miyayama	377
Advances in Transarterial Treatment: Drug-eluting Bead TACE	·· 378
EVIDENCE BASED MANAGEMENT OF HCC	
Bridging Pathologic Information into Clinics: The Role of Liver Biopsy in the Management of Hepatocellular Carcinoma	385
Surgery versus Locoregional Therapy for Early HCC ······ Su Jong Yu	387
Multimodal Treatments for Intermediate and Advanced Hepatocellular Carcinomas: Focused on the Non-Standard Options	392
Radiation Therapy in HCC: Implications from Korean Multicenter Registry Study	. 394
AUTHOR INDEX	399